Bots, editor, reviewer, Administrators
13,951
edits
Feed:All articles/Pretty: Difference between revisions
Jump to navigation
Jump to search
no edit summary
No edit summary |
No edit summary Tag: Reverted |
||
| Line 1,923: | Line 1,923: | ||
}, | }, | ||
{ | { | ||
"timestamp" : "2017-12-03T22:34: | "timestamp" : "2017-12-03T22:34:21Z", | ||
"briefDesignDescription" : " | "briefDesignDescription" : "PFO closure in cryptogenic stroke", | ||
"fulltexturl" : "http://www.nejm.org/doi/full/10.1056/ | "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1009639", | ||
"pageid" : | "pageid" : 1093, | ||
"pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/ | "pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa1009639", | ||
"trainingLevel" : " | "trainingLevel" : "Fellow", | ||
"citation" : " | "citation" : "Furlan AJ, <i>et al</i>. \"Closure or medical therapy for cryptogenic stroke with patent foramen ovale\". <i>The New England Journal of Medicine</i>. 2012. 366(11):991-999.", | ||
"subspecialties" : " | "subspecialties" : "Neurology;Cardiology", | ||
"expansion" : " | "expansion" : "Evaluation of the STARFlex Septal Closure System in Patients with a Stroke and/or Transient Ischemic Attack due to Presumed Paradoxical Embolism through a Patent Foramen Ovale", | ||
"statusUsableDate" : " | "statusUsableDate" : "2013-01-01", | ||
"briefResultsDescription" : " | "briefResultsDescription" : "PFO closure does not reduce recurrent stroke", | ||
"published" : " | "published" : "2012-03-15", | ||
"pageName" : " | "pageName" : "CLOSURE I", | ||
"diseases" : " | "diseases" : "Stroke;Patent Foramen Ovale;Transient Ischemic Attack", | ||
"abbreviation" : " | "abbreviation" : "CLOSURE I", | ||
"title" : " | "title" : "Closure or medical therapy for cryptogenic stroke with patent foramen ovale", | ||
"pmid" : " | "pmid" : "22417252" | ||
}, | }, | ||
{ | { | ||
"timestamp" : "2017-12-03T22:34: | "timestamp" : "2017-12-03T22:34:50Z", | ||
"briefDesignDescription" : " | "briefDesignDescription" : "Aspirin/clopidogrel duration after PCI", | ||
"fulltexturl" : "http://www.nejm.org/doi/full/10.1056/ | "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1409312", | ||
"pageid" : | "pageid" : 2264, | ||
"pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/ | "pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa1409312", | ||
"trainingLevel" : "Intern", | "trainingLevel" : "Intern", | ||
"citation" : " | "citation" : "Mauri L, <i>et al</i>. \"Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents\". <i>The New England Journal of Medicine</i>. 2014. 371(23):2155-2166.", | ||
"subspecialties" : "Cardiology", | "subspecialties" : "Cardiology", | ||
"expansion" : " | "expansion" : "Dual Antiplatelet Therapy", | ||
"statusUsableDate" : " | "statusUsableDate" : "2014-11-01", | ||
"briefResultsDescription" : " | "briefResultsDescription" : "Longer duration reduces stent thrombosis, MI, stroke, but increases mortality/bleeding", | ||
"published" : " | "published" : "2014-11-16", | ||
"pageName" : " | "pageName" : "DAPT", | ||
"diseases" : "Coronary Artery Disease | "diseases" : "Coronary Artery Disease;Myocardial Infarction;Stroke", | ||
"abbreviation" : " | "abbreviation" : "DAPT", | ||
"title" : " | "title" : "Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents", | ||
"pmid" : " | "pmid" : "25399658" | ||
}, | }, | ||
{ | { | ||
"timestamp" : "2020- | "timestamp" : "2020-09-22T18:22:21Z", | ||
"briefDesignDescription" : " | "briefDesignDescription" : "DASH diet in HTN", | ||
"fulltexturl" : "http://www.nejm.org/doi/full/10.1056/ | "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJM199704173361601", | ||
"pageid" : | "pageid" : 90, | ||
"pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/ | "pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJM199704173361601", | ||
"trainingLevel" : " | "trainingLevel" : "Student", | ||
"citation" : " | "citation" : "Appel LJ, <i>et al</i>. \"A clinical trial of the effects of dietary patterns on blood pressure\". <i>The New England Journal of Medicine</i>. 1997. 336(16):1117-1124.", | ||
"subspecialties" : " | "subspecialties" : "Cardiology;Nephrology", | ||
"expansion" : " | "expansion" : "Dietary Approaches to Stop Hypertension", | ||
"statusUsableDate" : " | "statusUsableDate" : "2012-04-01", | ||
"briefResultsDescription" : " | "briefResultsDescription" : "DASH diet reduces SBP and DBP", | ||
"published" : " | "published" : "1997-04-17", | ||
"pageName" : " | "pageName" : "DASH", | ||
"diseases" : " | "diseases" : "Hypertension", | ||
"abbreviation" : " | "abbreviation" : "DASH", | ||
"title" : " | "title" : "A clinical trial of the effects of dietary patterns on blood pressure", | ||
"pmid" : " | "pmid" : "9099655" | ||
}, | }, | ||
{ | { | ||
"timestamp" : " | "timestamp" : "2017-12-03T22:34:54Z", | ||
"briefDesignDescription" : " | "briefDesignDescription" : "Dual-chamber vs. ventricular backup pacing in ICD patients", | ||
"fulltexturl" : "http:// | "fulltexturl" : "http://jama.jamanetwork.com/article.aspx?volume", | ||
"pageid" : | "pageid" : 2713, | ||
"pdfurl" : | "pdfurl" : null, | ||
"trainingLevel" : "Resident", | "trainingLevel" : "Resident", | ||
"citation" : " | "citation" : "Wilkoff BL, <i>et al</i>. \"Dual-chamber pacing or ventricular backup pacing in patients with an implantable defibrillator\". <i>Journal of the American Medical Association</i>. 2002. 288(24):3115-3123.", | ||
"subspecialties" : "Cardiology", | "subspecialties" : "Cardiology", | ||
"expansion" : " | "expansion" : "Dual-chamber pacing or ventricular backup pacing in ICD patients", | ||
"statusUsableDate" : " | "statusUsableDate" : "2016-08-01", | ||
"briefResultsDescription" : " | "briefResultsDescription" : "Ventricular backup pacemaker superior to dual-chamber pacemaker", | ||
"published" : " | "published" : "2002-12-25", | ||
"pageName" : " | "pageName" : "DAVID", | ||
"diseases" : " | "diseases" : "Bradycardia", | ||
"abbreviation" : " | "abbreviation" : "DAVID", | ||
"title" : " | "title" : "Dual-chamber pacing or ventricular backup pacing in patients with an implantable defibrillator", | ||
"pmid" : " | "pmid" : "12495391" | ||
}, | }, | ||
{ | { | ||
"timestamp" : " | "timestamp" : "2020-01-25T11:34:00Z", | ||
"briefDesignDescription" : " | "briefDesignDescription" : "Thrombectomy 6-24 hours after stroke", | ||
"fulltexturl" : " | "fulltexturl" : "https://www.nejm.org/doi/full/10.1056/NEJMoa1706442", | ||
"pageid" : | "pageid" : 3529, | ||
"pdfurl" : " | "pdfurl" : "https://www.nejm.org/doi/pdf/10.1056/NEJMoa1706442", | ||
"trainingLevel" : " | "trainingLevel" : "Resident", | ||
"citation" : " | "citation" : "Nogueira RG, <i>et al</i>. \"Thrombectomy 6 to 24 Hours after Stroke with a Mismatch between Deficit and Infarct\". <i>The New England Journal of Medicine</i>. 2018. 378(1):11-21.", | ||
"subspecialties" : " | "subspecialties" : "Neurology", | ||
"expansion" : | "expansion" : "DWI or CTP Assessment with Clinical Mismatch in the Triage of Wake-Up and Late Presenting Strokes Undergoing Neurointervention with Trevo", | ||
"statusUsableDate" : "2020-01-23", | |||
"briefResultsDescription" : "Thrombectomy improved 90-day outcomes compared to standard care", | |||
"published" : "2018-01-04", | |||
"pageName" : "DAWN", | |||
"diseases" : "Stroke", | |||
"abbreviation" : "DAWN", | |||
"title" : "Thrombectomy 6 to 24 Hours after Stroke with a Mismatch between Deficit and Infarct", | |||
"pmid" : "29129157" | |||
"statusUsableDate" : " | |||
"briefResultsDescription" : " | |||
"published" : " | |||
"pageName" : " | |||
"diseases" : " | |||
"abbreviation" : " | |||
"title" : " | |||
"pmid" : " | |||
}, | }, | ||
{ | { | ||
"timestamp" : " | "timestamp" : "2012-09-16T11:23:12Z", | ||
"briefDesignDescription" : "Intensive glycemic therapy in T1DM", | |||
"fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJM199309303291401", | |||
"pageid" : 135, | |||
"pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJM199309303291401", | |||
"briefDesignDescription" : " | |||
"fulltexturl" : "http://www.nejm.org/doi/full/10.1056/ | |||
"pageid" : | |||
"pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/ | |||
"trainingLevel" : "Student", | "trainingLevel" : "Student", | ||
"citation" : " | "citation" : "DCCT Research Group. \"The Effect of Intensive Treatment of Diabetes on the Development and Progression of Long-Term Complications in Insulin-Dependent Diabetes Mellitus\". <i>The New England Journal of Medicine</i>. 1993. 329(14):977-986.", | ||
"subspecialties" : " | "subspecialties" : "Endocrinology", | ||
"expansion" : " | "expansion" : "Diabetes Control and Complications Trial", | ||
"statusUsableDate" : " | "statusUsableDate" : "2012-03-01", | ||
"briefResultsDescription" : " | "briefResultsDescription" : "Intensive therapy delays microvascular but not macrovascular complications in T1DM", | ||
"published" : " | "published" : "1993-09-30", | ||
"pageName" : " | "pageName" : "DCCT", | ||
"diseases" : " | "diseases" : "Diabetes Mellitus", | ||
"abbreviation" : " | "abbreviation" : "DCCT", | ||
"title" : " | "title" : "The Effect of Intensive Treatment of Diabetes on the Development and Progression of Long-Term Complications in Insulin-Dependent Diabetes Mellitus", | ||
"pmid" : " | "pmid" : "8366922" | ||
}, | }, | ||
{ | { | ||
"timestamp" : " | "timestamp" : "2014-06-13T04:45:33Z", | ||
"briefDesignDescription" : " | "briefDesignDescription" : "ICD vs. medical therapy in HFrEF", | ||
"fulltexturl" : "http://www.nejm.org/doi/full/10.1056/ | "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa033088", | ||
"pageid" : | "pageid" : 84, | ||
"pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/ | "pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa033088", | ||
"trainingLevel" : "Resident", | "trainingLevel" : "Resident", | ||
"citation" : " | "citation" : "Kadish A, <i>et al</i>. \"Prophylactic Defibrillator Implantation in Patients with Nonischemic Dilated Cardiomyopathy\". <i>The New England Journal of Medicine</i>. 2004. 350(21):2151-2158.", | ||
"subspecialties" : "Cardiology", | "subspecialties" : "Cardiology", | ||
"expansion" : "", | "expansion" : "Defibrillators in Non-Ischemic Cardiomyopathy Treatment Evaluation", | ||
"statusUsableDate" : " | "statusUsableDate" : "2012-03-01", | ||
"briefResultsDescription" : " | "briefResultsDescription" : "ICD reduced risk of arrhythmogenic sudden death, but not overall mortality", | ||
"published" : " | "published" : "2004-05-20", | ||
"pageName" : " | "pageName" : "DEFINITE", | ||
"diseases" : "Heart Failure", | "diseases" : "Heart Failure", | ||
"abbreviation" : " | "abbreviation" : "DEFINITE", | ||
"title" : " | "title" : "Prophylactic Defibrillator Implantation in Patients with Nonischemic Dilated Cardiomyopathy", | ||
"pmid" : " | "pmid" : "15152060" | ||
}, | }, | ||
{ | { | ||
"timestamp" : " | "timestamp" : "2021-10-04T20:25:15Z", | ||
"briefDesignDescription" : " | "briefDesignDescription" : "Ramelteon vs. placebo to prevent delirium", | ||
"fulltexturl" : " | "fulltexturl" : "http://jamanetwork.com/journals/jamapsychiatry/fullarticle/1831407", | ||
"pageid" : | "pageid" : 2806, | ||
"pdfurl" : " | "pdfurl" : "", | ||
"trainingLevel" : "Resident", | "trainingLevel" : "Resident", | ||
"citation" : " | "citation" : "Hatta K, <i>et al</i>. \"Preventive effects of ramelteon on delirium: a randomized placebo-controlled trial\". <i>JAMA Psychiatry</i>. 2014. 71(4):397-403.", | ||
"subspecialties" : " | "subspecialties" : "Psychiatry;Geriatrics", | ||
"expansion" : " | "expansion" : "Delirium Intervention Research for Improving Acute phase outcomes in Japan", | ||
"statusUsableDate" : " | "statusUsableDate" : "2021-09-30", | ||
"briefResultsDescription" : " | "briefResultsDescription" : "Ramelteon decreased risk of delirium in elderly patients", | ||
"published" : " | "published" : "2014-04-01", | ||
"pageName" : " | "pageName" : "DELIRIA-J", | ||
"diseases" : " | "diseases" : "Delirium", | ||
"abbreviation" : " | "abbreviation" : "DELIRIA-J", | ||
"title" : " | "title" : "Preventive effects of ramelteon on delirium: a randomized placebo-controlled trial", | ||
"pmid" : " | "pmid" : "24554232" | ||
}, | }, | ||
{ | { | ||
"timestamp" : " | "timestamp" : "2023-05-04T03:39:40Z", | ||
"briefDesignDescription" : " | "briefDesignDescription" : "Dapagliflozin in HFmrEF or HFpEF", | ||
"fulltexturl" : " | "fulltexturl" : "https://www.nejm.org/doi/10.1056/NEJMoa2206286", | ||
"pageid" : | "pageid" : 4921, | ||
"pdfurl" : " | "pdfurl" : "https://www.nejm.org/doi/pdf/10.1056/NEJMoa2206286", | ||
"trainingLevel" : " | "trainingLevel" : "Resident", | ||
"citation" : " | "citation" : "Solomon SD, <i>et al</i>. \"Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction\". <i>The New England Journal of Medicine</i>. 2022. 387(12):1089-1098.", | ||
"subspecialties" : " | "subspecialties" : "Cardiology", | ||
"expansion" : "Evaluation of | "expansion" : "Dapagliflozin Evaluation to Improve the Lives of Patients with Preserved Ejection Fraction Heart Failure", | ||
"statusUsableDate" : " | "statusUsableDate" : "2022-10-13", | ||
"briefResultsDescription" : " | "briefResultsDescription" : "Dapagliflozin reduces HF events in HFmrEF or HFpEF", | ||
"published" : " | "published" : "2022-09-22", | ||
"pageName" : " | "pageName" : "DELIVER", | ||
"diseases" : " | "diseases" : "Heart Failure", | ||
"abbreviation" : " | "abbreviation" : "DELIVER", | ||
"title" : " | "title" : "Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction", | ||
"pmid" : " | "pmid" : "36027570" | ||
}, | }, | ||
{ | { | ||
"timestamp" : "2018- | "timestamp" : "2018-02-01T20:15:39Z", | ||
"briefDesignDescription" : " | "briefDesignDescription" : "Oxygen for suspected MI", | ||
"fulltexturl" : "http://www.nejm.org/doi/full/10.1056/ | "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1706222", | ||
"pageid" : | "pageid" : 2970, | ||
"pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/ | "pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa1706222", | ||
"trainingLevel" : " | "trainingLevel" : "Student", | ||
"citation" : " | "citation" : "Hofmann R, <i>et al</i>. \"Oxygen therapy in suspected acute myocardial infarction\". <i>The New England Journal of Medicine</i>. 2017. 377(13):1240-1249.", | ||
"subspecialties" : "Cardiology", | "subspecialties" : "Cardiology", | ||
"expansion" : " | "expansion" : "Determination of the Role of Oxygen in Suspected Acute Myocardial Infarction", | ||
"statusUsableDate" : " | "statusUsableDate" : "2017-10-01", | ||
"briefResultsDescription" : " | "briefResultsDescription" : "Oxygen doesn't improve 1 year survival in MI", | ||
"published" : " | "published" : "2017-09-28", | ||
"pageName" : " | "pageName" : "DETO2X-AMI", | ||
"diseases" : " | "diseases" : "Myocardial Infarction", | ||
"abbreviation" : " | "abbreviation" : "DETO2X-AMI", | ||
"title" : " | "title" : "Oxygen therapy in suspected acute myocardial infarction", | ||
"pmid" : " | "pmid" : "28844200" | ||
}, | }, | ||
{ | { | ||
"timestamp" : " | "timestamp" : "2014-06-13T04:50:56Z", | ||
"briefDesignDescription" : " | "briefDesignDescription" : "Digoxin in HFrEF", | ||
"fulltexturl" : "http://www.nejm.org/doi/full/10.1056/ | "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJM199702203360801", | ||
"pageid" : | "pageid" : 89, | ||
"pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/ | "pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJM199702203360801", | ||
"trainingLevel" : "Resident", | "trainingLevel" : "Resident", | ||
"citation" : " | "citation" : "Gorlin R, <i>et al</i>. \"The effect of digoxin on mortality and morbidity in patients with heart failure\". <i>The New England Journal of Medicine</i>. 1997. 336(8):525-533.", | ||
"subspecialties" : "Cardiology", | "subspecialties" : "Cardiology", | ||
"expansion" : " | "expansion" : "Digitalis Investigation Group", | ||
"statusUsableDate" : "2012- | "statusUsableDate" : "2012-03-01", | ||
"briefResultsDescription" : " | "briefResultsDescription" : "Reduced hospitalizations, no mortality benefit", | ||
"published" : " | "published" : "1997-02-20", | ||
"pageName" : " | "pageName" : "DIG", | ||
"diseases" : " | "diseases" : "Heart Failure", | ||
"abbreviation" : " | "abbreviation" : "DIG", | ||
"title" : " | "title" : "The effect of digoxin on mortality and morbidity in patients with heart failure", | ||
"pmid" : " | "pmid" : "9036306" | ||
}, | }, | ||
{ | { | ||
"timestamp" : " | "timestamp" : "2020-09-14T19:26:41Z", | ||
"briefDesignDescription" : " | "briefDesignDescription" : "ICD for ICM shortly after MI", | ||
"fulltexturl" : " | "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa041489", | ||
"pageid" : | "pageid" : 1743, | ||
"pdfurl" : " | "pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa041489", | ||
"trainingLevel" : "Resident", | "trainingLevel" : "Resident", | ||
"citation" : " | "citation" : "Hohnloser SH, <i>et al</i>. \"Prophylactic use of an implantable cardioverter–defibrillator after acute myocardial infarction\". <i>The New England Journal of Medicine</i>. 2004. 351(24):2481-2488.", | ||
"subspecialties" : "Cardiology", | "subspecialties" : "Cardiology", | ||
"expansion" : " | "expansion" : "Defibrillator in Acute Myocardial Infarction Trial", | ||
"statusUsableDate" : " | "statusUsableDate" : "2016-04-01", | ||
"briefResultsDescription" : " | "briefResultsDescription" : "ICD reduces arrhythmia but not mortality", | ||
"published" : " | "published" : "2004-12-09", | ||
"pageName" : " | "pageName" : "DINAMIT", | ||
"diseases" : " | "diseases" : "Heart Failure;Myocardial Infarction", | ||
"abbreviation" : " | "abbreviation" : "DINAMIT", | ||
"title" : " | "title" : "Prophylactic use of an implantable cardioverter–defibrillator after acute myocardial infarction", | ||
"pmid" : " | "pmid" : "15590950" | ||
}, | }, | ||
{ | { | ||
"timestamp" : " | "timestamp" : "2019-10-17T17:40:21Z", | ||
"briefDesignDescription" : " | "briefDesignDescription" : "BMS vs. DES for saphenous vein graft PCI", | ||
"fulltexturl" : " | "fulltexturl" : "https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(18)30801-8/fulltext", | ||
"pageid" : | "pageid" : 3743, | ||
"pdfurl" : " | "pdfurl" : "", | ||
"trainingLevel" : "Resident", | "trainingLevel" : "Resident", | ||
"citation" : " | "citation" : "Brilakis ES, <i>et al</i>. \"Drug-eluting stents versus bare-metal stents in saphenous vein grafts: a double-blind, randomised trial\". <i>Lancet</i>. 2018. 391(10134):1997-2007.", | ||
"subspecialties" : "Cardiology", | "subspecialties" : "Cardiology", | ||
"expansion" : " | "expansion" : "Rationale and design of the drug-eluting stents vs bare-metal stents in saphenous vein graft angioplasty", | ||
"statusUsableDate" : " | "statusUsableDate" : "2018-11-27", | ||
"briefResultsDescription" : " | "briefResultsDescription" : "BMS noninferior to DES for saphenous vein graft PCI", | ||
"published" : " | "published" : "2018-05-19", | ||
"pageName" : " | "pageName" : "DIVA", | ||
"diseases" : " | "diseases" : "Coronary Artery Disease", | ||
"abbreviation" : " | "abbreviation" : "DIVA", | ||
"title" : " | "title" : "Drug-eluting stents versus bare-metal stents in saphenous vein grafts: a double-blind, randomised trial", | ||
"pmid" : " | "pmid" : "29759512" | ||
}, | }, | ||
{ | { | ||
"timestamp" : " | "timestamp" : "2019-07-18T20:41:06Z", | ||
"briefDesignDescription" : " | "briefDesignDescription" : "D-dimer based anticoagulation discontinuation", | ||
"fulltexturl" : " | "fulltexturl" : "https://onlinelibrary.wiley.com/doi/full/10.1111/jth.14458", | ||
"pageid" : | "pageid" : 4089, | ||
"pdfurl" : " | "pdfurl" : "https://onlinelibrary.wiley.com/doi/pdf/10.1111/jth.14458", | ||
"trainingLevel" : " | "trainingLevel" : "Fellow", | ||
"citation" : " | "citation" : "Kearon C, <i>et al</i>. \"Long-term risk of recurrence in patients with a first unprovoked venous thromboembolism managed according to D-dimer results: a cohort study\". <i>Journal of Thrombosis and Hemostasis</i>. 2019. 17(7):1144-52.", | ||
"subspecialties" : " | "subspecialties" : "Hematology", | ||
"expansion" : " | "expansion" : "D-dimer Optimal Duration Study", | ||
"statusUsableDate" : " | "statusUsableDate" : "2019-07-18", | ||
"briefResultsDescription" : " | "briefResultsDescription" : "D-dimer based discontinuation effective in women, not for men", | ||
"published" : " | "published" : "2019-01-18", | ||
"pageName" : " | "pageName" : "DODS", | ||
"diseases" : " | "diseases" : "Venous Thromboembolism;Pulmonary Embolism;Deep Vein Thrombosis", | ||
"abbreviation" : " | "abbreviation" : "DODS", | ||
"title" : " | "title" : "Long-term risk of recurrence in patients with a first unprovoked venous thromboembolism managed according to D-dimer results: a cohort study", | ||
"pmid" : " | "pmid" : "31033194" | ||
}, | }, | ||
{ | { | ||
"timestamp" : " | "timestamp" : "2019-05-23T17:58:08Z", | ||
"briefDesignDescription" : " | "briefDesignDescription" : "Donor HCV positive heart and lung transplant", | ||
"fulltexturl" : " | "fulltexturl" : "https://www.nejm.org/doi/full/10.1056/NEJMoa1812406", | ||
"pageid" : | "pageid" : 4066, | ||
"pdfurl" : " | "pdfurl" : "https://www.nejm.org/doi/pdf/10.1056/NEJMoa1812406", | ||
"trainingLevel" : "Resident", | "trainingLevel" : "Resident", | ||
"citation" : " | "citation" : "Woolley AE, <i>et al</i>. \"Heart and Lung Transplants from HCV-Infected Donors to Uninfected Recipients\". <i>The New England Journal of Medicine</i>. 2019. 380(17):1606-1617.", | ||
"subspecialties" : "Cardiology", | "subspecialties" : "Cardiology", | ||
"expansion" : "", | "expansion" : "Donors of Hepatitis C NAT Positive Thoracic Allografts for Transplantation Evaluation in Non-HCV Recipients", | ||
"statusUsableDate" : " | "statusUsableDate" : "2019-05-17", | ||
"briefResultsDescription" : " | "briefResultsDescription" : "Donor HCV+ heart & lung transplant is feasible", | ||
"published" : " | "published" : "2019-04-25", | ||
"pageName" : " | "pageName" : "DONATE-HCV", | ||
"diseases" : " | "diseases" : "Heart Failure;Respiratory Failure", | ||
"abbreviation" : " | "abbreviation" : "DONATE HCV", | ||
"title" : " | "title" : "Heart and Lung Transplants from HCV-Infected Donors to Uninfected Recipients", | ||
"pmid" : " | "pmid" : "30946553" | ||
}, | }, | ||
{ | { | ||
"timestamp" : " | "timestamp" : "2022-09-15T20:00:28Z", | ||
"briefDesignDescription" : "Diuretic dosing in acute HF", | |||
"fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1005419", | |||
"pageid" : 1457, | |||
"pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa1005419", | |||
"briefDesignDescription" : " | |||
"fulltexturl" : "http://www.nejm.org/doi/full/10.1056/ | |||
"pageid" : | |||
"pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/ | |||
"trainingLevel" : "Intern", | "trainingLevel" : "Intern", | ||
"citation" : " | "citation" : "Felker GM, <i>et al</i>. \"Diuretic strategies in patients with acute decompensated heart failure\". <i>The New England Journal of Medicine</i>. 2011. 364(9):797-805.", | ||
"subspecialties" : "Cardiology", | "subspecialties" : "Cardiology", | ||
"expansion" : " | "expansion" : "Diuretic Optimization Strategies Evaluation", | ||
"statusUsableDate" : " | "statusUsableDate" : "2013-06-01", | ||
"briefResultsDescription" : " | "briefResultsDescription" : "High-dose better than low-dose, continuous infusions no better than intermittent IV boluses", | ||
"published" : " | "published" : "2011-03-03", | ||
"pageName" : " | "pageName" : "DOSE", | ||
"diseases" : "Heart Failure", | "diseases" : "Heart Failure", | ||
"abbreviation" : " | "abbreviation" : "DOSE", | ||
"title" : " | "title" : "Diuretic strategies in patients with acute decompensated heart failure", | ||
"pmid" : " | "pmid" : "21366472" | ||
}, | }, | ||
{ | { | ||
"timestamp" : " | "timestamp" : "2018-05-31T18:34:46Z", | ||
"briefDesignDescription" : " | "briefDesignDescription" : "Metformin and intensive lifestyle in prediabetes", | ||
"fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa012512", | |||
"pageid" : 2494, | |||
"pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa012512", | |||
"fulltexturl" : "http://www.nejm.org/doi/full/10.1056/ | |||
"pageid" : | |||
"pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/ | |||
"trainingLevel" : "Student", | "trainingLevel" : "Student", | ||
"citation" : " | "citation" : "Knowler WC, <i>et al</i>. \"Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin\". <i>The New England Journal of Medicine</i>. 2002. 346(6):393-403.", | ||
"subspecialties" : " | "subspecialties" : "Endocrinology", | ||
"expansion" : " | "expansion" : "Diabetes Prevention Program", | ||
"statusUsableDate" : " | "statusUsableDate" : "2018-05-31", | ||
"briefResultsDescription" : " | "briefResultsDescription" : "Metformin and intensive lifestyle reduce incidence of diabetes", | ||
"published" : " | "published" : "2002-02-07", | ||
"pageName" : " | "pageName" : "DPP", | ||
"diseases" : " | "diseases" : "Prediabetes;Diabetes Mellitus", | ||
"abbreviation" : " | "abbreviation" : "DPP", | ||
"title" : " | "title" : "Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin", | ||
"pmid" : " | "pmid" : "11832527" | ||
}, | }, | ||
{ | { | ||
"timestamp" : "2017-12- | "timestamp" : "2017-12-03T22:35:03Z", | ||
"briefDesignDescription" : " | "briefDesignDescription" : "Duct tape vs. cryotherapy for warts", | ||
"fulltexturl" : " | "fulltexturl" : "", | ||
"pageid" : | "pageid" : 1579, | ||
"pdfurl" : "http:// | "pdfurl" : "http://archpedi.jamanetwork.com/data/Journals/PEDS/5052/POA20075.pdf", | ||
"trainingLevel" : "Student", | "trainingLevel" : "Student", | ||
"citation" : " | "citation" : "Focht DR, <i>et al</i>. \"The efficacy of duct tape vs cryotherapy in the treatment of verruca vulgaris (the common wart)\". <i>Archives of Pediatric and Adolescent Medicine</i>. 2002. 156:971-974.", | ||
"subspecialties" : " | "subspecialties" : "Pediatrics;Dermatology", | ||
"expansion" : " | "expansion" : "", | ||
"statusUsableDate" : " | "statusUsableDate" : "2013-07-01", | ||
"briefResultsDescription" : " | "briefResultsDescription" : "Duct tape superior to cryotherapy for wart resolution", | ||
"published" : " | "published" : "2002-10-01", | ||
"pageName" : " | "pageName" : "Duct Tape for Treatment of the Common Wart", | ||
"diseases" : " | "diseases" : "Warts", | ||
"abbreviation" : " | "abbreviation" : "", | ||
"title" : " | "title" : "The efficacy of duct tape vs cryotherapy in the treatment of verruca vulgaris (the common wart)", | ||
"pmid" : " | "pmid" : "12361440" | ||
}, | }, | ||
{ | { | ||
"timestamp" : " | "timestamp" : "2018-03-29T18:30:43Z", | ||
"briefDesignDescription" : " | "briefDesignDescription" : "Fecal transplant in C. difficile", | ||
"fulltexturl" : " | "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1205037", | ||
"pageid" : | "pageid" : 1226, | ||
"pdfurl" : "", | "pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa1205037", | ||
"trainingLevel" : " | "trainingLevel" : "Intern", | ||
"citation" : " | "citation" : "Van Nood E, <i>et al</i>. \"Duodenal Infusion of Donor Feces for Recurrent Clostridium difficile\". <i>The New England Journal of Medicine</i>. 2013. 368(5):407-415.", | ||
"subspecialties" : "Infectious Disease | "subspecialties" : "Gastroenterology;Infectious Disease", | ||
"expansion" : "", | "expansion" : "", | ||
"statusUsableDate" : " | "statusUsableDate" : "2013-02-01", | ||
"briefResultsDescription" : " | "briefResultsDescription" : "Fecal transplant better than vancomycin in C. difficile", | ||
"published" : " | "published" : "2013-01-31", | ||
"pageName" : " | "pageName" : "Duodenal Infusion of Donor Feces for Recurrent Clostridium difficile", | ||
"diseases" : " | "diseases" : "Clostridium difficile", | ||
"abbreviation" : "", | "abbreviation" : "", | ||
"title" : " | "title" : "Duodenal Infusion of Donor Feces for Recurrent Clostridium difficile", | ||
"pmid" : " | "pmid" : "23323867" | ||
}, | }, | ||
{ | { | ||
"timestamp" : " | "timestamp" : "2017-12-03T22:35:32Z", | ||
"briefDesignDescription" : " | "briefDesignDescription" : "Palliative care in NSCLC", | ||
"fulltexturl" : "http://www. | "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1000678", | ||
"pageid" : | "pageid" : 466, | ||
"pdfurl" : "http:// | "pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa1000678", | ||
"trainingLevel" : " | "trainingLevel" : "Intern", | ||
"citation" : " | "citation" : "Temel JS, <i>et al</i>. \"Early Palliative Care for Patients with Metastatic Non-Small-Cell Lung Cancer\". <i>The New England Journal of Medicine</i>. 2010. 363(8):733-742.", | ||
"subspecialties" : " | "subspecialties" : "Oncology;Palliative Care", | ||
"expansion" : | "expansion" : null, | ||
"statusUsableDate" : " | "statusUsableDate" : "2012-06-01", | ||
"briefResultsDescription" : " | "briefResultsDescription" : "Palliative care ↑mood, ↑QOL, ↑survival, ↓aggressive care", | ||
"published" : "2010- | "published" : "2010-08-19", | ||
"pageName" : " | "pageName" : "Early Palliative Care", | ||
"diseases" : " | "diseases" : "Lung Cancer", | ||
"abbreviation" : | "abbreviation" : null, | ||
"title" : " | "title" : "Early Palliative Care for Patients with Metastatic Non-Small-Cell Lung Cancer", | ||
"pmid" : " | "pmid" : "20818875" | ||
}, | }, | ||
{ | { | ||
"timestamp" : " | "timestamp" : "2018-08-30T17:24:07Z", | ||
"briefDesignDescription" : " | "briefDesignDescription" : "Early TIPS in high-risk cirrhotic variceal bleeding", | ||
"fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa0910102", | |||
"pageid" : 2661, | |||
"pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa0910102", | |||
"fulltexturl" : " | |||
"pageid" : | |||
"pdfurl" : " | |||
"trainingLevel" : "Resident", | "trainingLevel" : "Resident", | ||
"citation" : " | "citation" : "García-Pagán JC, <i>et al</i>. \"Early use of TIPS in patients with cirrhosis and variceal bleeding\". <i>The New England Journal of Medicine</i>. 2010. 362(25):2370-2379.", | ||
"subspecialties" : " | "subspecialties" : "Gastroenterology;Interventional Radiology", | ||
"expansion" : " | "expansion" : "", | ||
"statusUsableDate" : " | "statusUsableDate" : "2018-08-30", | ||
"briefResultsDescription" : " | "briefResultsDescription" : "Early TIPS reduces rates of treatment failure and improves 1-year survival", | ||
"published" : "2010-06-24", | |||
"pageName" : "Early TIPS", | |||
"diseases" : "Cirrhosis;Gastrointestinal Hemorrhage", | |||
"abbreviation" : "Early TIPS", | |||
"title" : "Early use of TIPS in patients with cirrhosis and variceal bleeding", | |||
"pmid" : "20573925" | |||
"published" : "2010- | |||
"pageName" : " | |||
"diseases" : " | |||
"abbreviation" : " | |||
"title" : " | |||
"pmid" : " | |||
}, | }, | ||
{ | { | ||
"timestamp" : "2021-11-08T18:52:31Z", | |||
"briefDesignDescription" : "Cryoablation vs. antiarrhythmics in AF", | |||
"fulltexturl" : "https://www.nejm.org/doi/full/10.1056/NEJMoa2029980", | |||
"pageid" : 4406, | |||
"pdfurl" : "https://www.nejm.org/doi/full/10.1056/NEJMoa2029980", | |||
"timestamp" : "2021 | |||
"briefDesignDescription" : " | |||
"fulltexturl" : " | |||
"pageid" : | |||
"pdfurl" : " | |||
"trainingLevel" : "Resident", | "trainingLevel" : "Resident", | ||
"citation" : " | "citation" : "Andrade J, <i>et al</i>. \"Cryoablation or Drug Therapy for Initial Treatment of Atrial Fibrillation\". <i>The New England Journal of Medicine</i>. 2021. 384(4):305-315.", | ||
"subspecialties" : "Cardiology", | "subspecialties" : "Cardiology", | ||
"expansion" : " | "expansion" : "Early Aggressive Invasive Intervention for Atrial Fibrillation", | ||
"statusUsableDate" : " | "statusUsableDate" : "2021-10-14", | ||
"briefResultsDescription" : " | "briefResultsDescription" : "Cryoablation with lower tachyarrhythmia recurrence than antiarrhythmics.", | ||
"published" : " | "published" : "2021-01-28", | ||
"pageName" : " | "pageName" : "EARLY-AF", | ||
"diseases" : " | "diseases" : "Atrial Fibrillation", | ||
"abbreviation" : " | "abbreviation" : "EARLY-AF", | ||
"title" : " | "title" : "Cryoablation or Drug Therapy for Initial Treatment of Atrial Fibrillation", | ||
"pmid" : " | "pmid" : "33197159" | ||
}, | }, | ||
{ | { | ||
"timestamp" : " | "timestamp" : "2019-09-19T17:42:49Z", | ||
"briefDesignDescription" : " | "briefDesignDescription" : "Early surgery in endocarditis", | ||
"fulltexturl" : "http://www.nejm.org/doi/full/10.1056/ | "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1112843", | ||
"pageid" : | "pageid" : 2939, | ||
"pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/ | "pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa1112843", | ||
"trainingLevel" : "Resident", | "trainingLevel" : "Resident", | ||
"citation" : " | "citation" : "Kang DH, <i>et al</i>. \"Early surgery versus conventional treatment for infective endocarditis\". <i>The New England Journal of Medicine</i>. 2012. 366(26):2466-73.", | ||
"subspecialties" : "Cardiology", | "subspecialties" : "Cardiology;Infectious Disease;Surgery", | ||
"expansion" : " | "expansion" : "Early Surgery versus Conventional Treatment in Infective Endocarditis", | ||
"statusUsableDate" : " | "statusUsableDate" : "2019-09-19", | ||
"briefResultsDescription" : " | "briefResultsDescription" : "Early surgery improves outcomes in infective endocarditis", | ||
"published" : " | "published" : "2012-06-28", | ||
"pageName" : " | "pageName" : "EASE", | ||
"diseases" : " | "diseases" : "Endocarditis", | ||
"abbreviation" : " | "abbreviation" : "EASE", | ||
"title" : " | "title" : "Early surgery versus conventional treatment for infective endocarditis", | ||
"pmid" : " | "pmid" : "22738096" | ||
}, | }, | ||
{ | { | ||
"timestamp" : " | "timestamp" : "2021-02-09T14:57:23Z", | ||
"briefDesignDescription" : " | "briefDesignDescription" : "Early rhythm vs. rate control in AF", | ||
"fulltexturl" : " | "fulltexturl" : "https://www.nejm.org/doi/pdf/10.1056/NEJMoa2019422", | ||
"pageid" : | "pageid" : 4399, | ||
"pdfurl" : " | "pdfurl" : "https://www.nejm.org/doi/pdf/10.1056/NEJMoa2019422", | ||
"trainingLevel" : "Resident", | "trainingLevel" : "Resident", | ||
"citation" : " | "citation" : "Kirchhof P, <i>et al</i>. \"Early rhythm-control therapy in patients with atrial fibrillation\". <i>The New England Journal of Medicine</i>. 2020. 383(14):1305-1316.", | ||
"subspecialties" : "Cardiology", | "subspecialties" : "Cardiology", | ||
"expansion" : " | "expansion" : "The Early Treatment of Atrial Fibrillation for Stroke Prevention Trial", | ||
"statusUsableDate" : " | "statusUsableDate" : "2021-01-28", | ||
"briefResultsDescription" : " | "briefResultsDescription" : "Early rhythm control with fewer CVD events.", | ||
"published" : " | "published" : "2020-10-01", | ||
"pageName" : " | "pageName" : "EAST-AFNET 4", | ||
"diseases" : " | "diseases" : "Atrial Fibrillation", | ||
"abbreviation" : " | "abbreviation" : "EAST-AFNET 4", | ||
"title" : " | "title" : "Early rhythm-control therapy in patients with atrial fibrillation", | ||
"pmid" : " | "pmid" : "32865375" | ||
}, | }, | ||
{ | { | ||
"timestamp" : "2017- | "timestamp" : "2017-04-20T01:11:46Z", | ||
"briefDesignDescription" : " | "briefDesignDescription" : "Alteplase 3-4.5h after stroke", | ||
"fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa0804656", | |||
"pageid" : 115, | |||
"pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa0804656", | |||
"fulltexturl" : "http://www.nejm.org/doi/full/10.1056/ | |||
"pageid" : | |||
"pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/ | |||
"trainingLevel" : "Intern", | "trainingLevel" : "Intern", | ||
"citation" : " | "citation" : "Hacke W, <i>et al</i>. \"Thrombolysis with Alteplase 3 to 4.5 Hours after Acute Ischemic Stroke\". <i>The New England Journal of Medicine</i>. 2008. 359(13):1317-1329.", | ||
"subspecialties" : " | "subspecialties" : "Neurology", | ||
"expansion" : | "expansion" : "European Cooperative Acute Stroke Study III", | ||
"statusUsableDate" : " | "statusUsableDate" : "2012-03-01", | ||
"briefResultsDescription" : " | "briefResultsDescription" : "Alteplase improves neurological outcomes at 3 months", | ||
"published" : " | "published" : "2008-09-25", | ||
"pageName" : " | "pageName" : "ECASS III", | ||
"diseases" : " | "diseases" : "Stroke", | ||
"abbreviation" : | "abbreviation" : "ECASS III", | ||
"title" : " | "title" : "Thrombolysis with Alteplase 3 to 4.5 Hours after Acute Ischemic Stroke", | ||
"pmid" : " | "pmid" : "18815396" | ||
}, | }, | ||
{ | { | ||
"timestamp" : " | "timestamp" : "2024-06-27T17:56:09Z", | ||
"briefDesignDescription" : " | "briefDesignDescription" : "Levetiracetam vs. phenytoin in status epilepticus", | ||
"fulltexturl" : " | "fulltexturl" : "https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(19)30724-X/fulltext", | ||
"pageid" : | "pageid" : 4086, | ||
"pdfurl" : " | "pdfurl" : "https://www.thelancet.com/action/showPdf?pii", | ||
"trainingLevel" : " | "trainingLevel" : "Resident", | ||
"citation" : " | "citation" : "Lyttle MD, <i>et al</i>. \"Levetiracetam versus phenytoin for second-line treatment of paediatric convulsive status epilepticus (EcLiPSE): a multicentre, open-label, randomised trial.\". <i>Lancet</i>. 2019. 393(10186):2125-2134.", | ||
"subspecialties" : " | "subspecialties" : "Emergency Medicine;Pediatrics;Neurology", | ||
"expansion" : " | "expansion" : "Emergency treatment with Levetiracetam or Phenytoin in convulsive Status Epilepticus in children", | ||
"statusUsableDate" : " | "statusUsableDate" : "2024-05-16", | ||
"briefResultsDescription" : " | "briefResultsDescription" : "Levetiracetam is non-inferior to phenytoin", | ||
"published" : " | "published" : "2019-05-25", | ||
"pageName" : " | "pageName" : "EcLiPSE", | ||
"diseases" : " | "diseases" : "Status Epilepticus", | ||
"abbreviation" : " | "abbreviation" : "EcLiPSE", | ||
"title" : " | "title" : "Levetiracetam versus phenytoin for second-line treatment of paediatric convulsive status epilepticus (EcLiPSE): a multicentre, open-label, randomised trial.", | ||
"pmid" : " | "pmid" : "31005385" | ||
}, | }, | ||
{ | { | ||
"timestamp" : " | "timestamp" : "2020-08-01T19:26:48Z", | ||
"briefDesignDescription" : " | "briefDesignDescription" : "CEA in symptomatic carotid stenosis", | ||
"fulltexturl" : "http://www. | "fulltexturl" : "http://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2897%2909292-1", | ||
"pageid" : | "pageid" : 2354, | ||
"pdfurl" : " | "pdfurl" : "", | ||
"trainingLevel" : "Intern", | "trainingLevel" : "Intern", | ||
"citation" : " | "citation" : "ECST Writers. \"Randomised trial of endarterectomy for recently symptomatic carotid stenosis: Final results of the MRC European Carotid Surgery Trial (ECST)\". <i>The Lancet</i>. 1998. 351(9113):1379-1387.", | ||
"subspecialties" : " | "subspecialties" : "Surgery;Neurology", | ||
"expansion" : "", | "expansion" : "European Carotid Surgery Trial", | ||
"statusUsableDate" : " | "statusUsableDate" : "2015-08-01", | ||
"briefResultsDescription" : " | "briefResultsDescription" : "CEA improves outcomes in patients with ≥80% symptomatic carotid stenosis", | ||
"published" : " | "published" : "1998-05-09", | ||
"pageName" : " | "pageName" : "ECST", | ||
"diseases" : " | "diseases" : "Carotid Stenosis;Stroke", | ||
"abbreviation" : "", | "abbreviation" : "ECST", | ||
"title" : " | "title" : "Randomised trial of endarterectomy for recently symptomatic carotid stenosis: Final results of the MRC European Carotid Surgery Trial (ECST)", | ||
"pmid" : "9593407" | |||
"pmid" : " | |||
}, | }, | ||
{ | { | ||
"timestamp" : " | "timestamp" : "2013-03-12T08:18:42Z", | ||
"briefDesignDescription" : " | "briefDesignDescription" : "Intensive glycemic therapy in T1DM", | ||
"fulltexturl" : "http://www.nejm.org/doi/full/10.1056/ | "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa052187", | ||
"pageid" : | "pageid" : 136, | ||
"pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/ | "pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa052187", | ||
"trainingLevel" : " | "trainingLevel" : "intern", | ||
"citation" : " | "citation" : "Nathan DM, <i>et al</i>. \"Intensive Diabetes Treatment and Cardiovascular Disease in Patients with Type 1 Diabetes\". <i>The New England Journal of Medicine</i>. 2005. 353(25):2643-2653.", | ||
"subspecialties" : " | "subspecialties" : "Endocrinology", | ||
"expansion" : " | "expansion" : "Epidemiology of Diabetes Interventions and Complications", | ||
"statusUsableDate" : " | "statusUsableDate" : "2012-03-01", | ||
"briefResultsDescription" : " | "briefResultsDescription" : "Intensive therapy associated with fewer cardiovascular complications", | ||
"published" : " | "published" : "2005-12-22", | ||
"pageName" : " | "pageName" : "EDIC", | ||
"diseases" : " | "diseases" : "Diabetes Mellitus", | ||
"abbreviation" : " | "abbreviation" : "EDIC", | ||
"title" : " | "title" : "Intensive Diabetes Treatment and Cardiovascular Disease in Patients with Type 1 Diabetes", | ||
"pmid" : " | "pmid" : "16371630" | ||
}, | }, | ||
{ | { | ||
"timestamp" : " | "timestamp" : "2017-12-03T22:35:08Z", | ||
"briefDesignDescription" : " | "briefDesignDescription" : "Rivaroxaban after VTE treatment", | ||
"fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1700518", | |||
"pageid" : 2927, | |||
"pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa1700518", | |||
"fulltexturl" : "http://www.nejm.org/doi/full/10.1056/ | |||
"pageid" : | |||
"pdfurl" : " | |||
"trainingLevel" : "Resident", | "trainingLevel" : "Resident", | ||
"citation" : " | "citation" : "Weitz JI, <i>et al</i>. \"Rivaroxaban or Aspirin for Extended Treatment of Venous Thromboembolism\". <i>The New England Journal of Medicine</i>. 2017. 376(13):1211-22.", | ||
"subspecialties" : " | "subspecialties" : "Hematology", | ||
"expansion" : " | "expansion" : "Reduced-dosed Rivaroxaban in the Long-term Prevention of Recurrent Symptomatic Venous Thromboembolism", | ||
"statusUsableDate" : " | "statusUsableDate" : "2017-07-01", | ||
"briefResultsDescription" : " | "briefResultsDescription" : "Rivaroxaban reduces recurrent VTE", | ||
"published" : " | "published" : "2017-03-30", | ||
"pageName" : " | "pageName" : "EINSTEIN CHOICE", | ||
"diseases" : " | "diseases" : "Venous Thromboembolism;Deep Vein Thrombosis;Pulmonary Embolism", | ||
"abbreviation" : " | "abbreviation" : "EINSTEIN CHOICE", | ||
"title" : " | "title" : "Rivaroxaban or Aspirin for Extended Treatment of Venous Thromboembolism", | ||
"pmid" : " | "pmid" : "28316279" | ||
}, | }, | ||
{ | { | ||
"timestamp" : "2017-12-03T22: | "timestamp" : "2017-12-03T22:35:09Z", | ||
"briefDesignDescription" : " | "briefDesignDescription" : "Rivaroxaban vs. warfarin in PE", | ||
"fulltexturl" : "http://www.nejm.org/doi/full/10.1056/ | "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1113572", | ||
"pageid" : | "pageid" : 1519, | ||
"pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/ | "pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa1113572", | ||
"trainingLevel" : " | "trainingLevel" : "Student", | ||
"citation" : " | "citation" : "Büller HR, <i>et al</i>. \"Oral rivaroxaban for the treatment of symptomatic pulmonary embolism\". <i>The New England Journal of Medicine</i>. 2012. 366(14):1287-1297.", | ||
"subspecialties" : " | "subspecialties" : "Hematology;Pulmonology", | ||
"expansion" : " | "expansion" : "", | ||
"statusUsableDate" : " | "statusUsableDate" : "2013-07-01", | ||
"briefResultsDescription" : " | "briefResultsDescription" : "Rivaroxaban is noninferior to warfarin in PE treatment", | ||
"published" : " | "published" : "2012-04-05", | ||
"pageName" : " | "pageName" : "EINSTEIN-PE", | ||
"diseases" : " | "diseases" : "Pulmonary Embolism;Venous Thromboembolism", | ||
"abbreviation" : " | "abbreviation" : "EINSTEIN-PE", | ||
"title" : " | "title" : "Oral rivaroxaban for the treatment of symptomatic pulmonary embolism", | ||
"pmid" : " | "pmid" : "22449293" | ||
}, | }, | ||
{ | { | ||
"timestamp" : " | "timestamp" : "2018-05-27T16:17:38Z", | ||
"briefDesignDescription" : " | "briefDesignDescription" : "Immunosuppression after kidney transplant", | ||
"fulltexturl" : "http://www.nejm.org/doi/full/10.1056/ | "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa067411", | ||
"pageid" : | "pageid" : 2324, | ||
"pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/ | "pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa067411", | ||
"trainingLevel" : " | "trainingLevel" : "Resident", | ||
"citation" : " | "citation" : "Ekberg H, <i>et al</i>. \"Reduced exposure to calcineurin inhibitors in renal transplantation\". <i>The New England Journal of Medicine</i>. 2007. 357(25):2562-2575.", | ||
"subspecialties" : " | "subspecialties" : "Nephrology", | ||
"expansion" : " | "expansion" : "Efficacy Limiting Toxicity Elimination-Symphony", | ||
"statusUsableDate" : " | "statusUsableDate" : "2015-02-01", | ||
"briefResultsDescription" : " | "briefResultsDescription" : "Daclizumab, mycophenolate, steroids, and tacrolimus beneficial", | ||
"published" : " | "published" : "2007-12-20", | ||
"pageName" : " | "pageName" : "ELITE-Symphony", | ||
"diseases" : " | "diseases" : "Kidney Transplant", | ||
"abbreviation" : " | "abbreviation" : "ELITE-Symphony", | ||
"title" : " | "title" : "Reduced exposure to calcineurin inhibitors in renal transplantation", | ||
"pmid" : " | "pmid" : "18094377" | ||
}, | }, | ||
{ | { | ||
"timestamp" : " | "timestamp" : "2018-09-13T17:28:08Z", | ||
"briefDesignDescription" : " | "briefDesignDescription" : "Extended EKG monitoring after cryptogenic stroke", | ||
"fulltexturl" : " | "fulltexturl" : "https://www.nejm.org/doi/10.1056/NEJMoa1311376", | ||
"pageid" : | "pageid" : 2403, | ||
"pdfurl" : | "pdfurl" : "https://www.nejm.org/doi/pdf/10.1056/NEJMoa1311376", | ||
"trainingLevel" : "Resident", | "trainingLevel" : "Resident", | ||
"citation" : " | "citation" : "Gladstone DJ, <i>et al</i>. \"Atrial Fibrillation in Patients with Cryptogenic Stroke\". <i>The New England Journal of Medicine</i>. 2014. 370(26):2467-2477.", | ||
"subspecialties" : "Cardiology", | "subspecialties" : "Neurology;Cardiology", | ||
"expansion" : " | "expansion" : "30-Day Cardiac Event Monitor Belt for Recording Atrial Fibrillation after a Cerebral Ischemic Event", | ||
"statusUsableDate" : " | "statusUsableDate" : "2018-09-13", | ||
"briefResultsDescription" : " | "briefResultsDescription" : "Extended EKG monitoring detects AF more frequently than 24-hour monitoring", | ||
"published" : " | "published" : "2014-06-26", | ||
"pageName" : " | "pageName" : "EMBRACE", | ||
"diseases" : " | "diseases" : "Stroke;Atrial Fibrillation", | ||
"abbreviation" : " | "abbreviation" : "EMBRACE", | ||
"title" : " | "title" : "Atrial Fibrillation in Patients with Cryptogenic Stroke", | ||
"pmid" : " | "pmid" : "24963566" | ||
}, | }, | ||
{ | { | ||
"timestamp" : " | "timestamp" : "2021-07-28T13:09:44Z", | ||
"briefDesignDescription" : " | "briefDesignDescription" : "T-DM1 in metastatic breast cancer", | ||
"fulltexturl" : " | "fulltexturl" : "http://www.nejm.org/doi/abs/10.1056/NEJMoa1209124", | ||
"pageid" : | "pageid" : 1257, | ||
"pdfurl" : " | "pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa1209124", | ||
"trainingLevel" : " | "trainingLevel" : "fellow", | ||
"citation" : " | "citation" : "Verma S, <i>et al</i>. \"Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer\". <i>The New England Journal of Medicine</i>. 2012. 367(19):1783-1791.", | ||
"subspecialties" : " | "subspecialties" : "Oncology", | ||
"expansion" : " | "expansion" : "Emtansine vs. Capecitabine+Lapatinib in Patients with HER2-Positive Locally Advanced or Metastatic Breast Cancer", | ||
"statusUsableDate" : " | "statusUsableDate" : "2013-04-01", | ||
"briefResultsDescription" : " | "briefResultsDescription" : "T-DM1 prolongs PFS in metastatic breast cancer", | ||
"published" : " | "published" : "2012-11-08", | ||
"pageName" : " | "pageName" : "EMILIA", | ||
"diseases" : " | "diseases" : "Breast Cancer", | ||
"abbreviation" : " | "abbreviation" : "EMILIA", | ||
"title" : " | "title" : "Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer", | ||
"pmid" : " | "pmid" : "23020162" | ||
}, | }, | ||
{ | { | ||
"timestamp" : " | "timestamp" : "2023-12-14T18:27:14Z", | ||
"briefDesignDescription" : " | "briefDesignDescription" : "Empagliflozin for CV outcomes in T2DM", | ||
"fulltexturl" : "http://www.nejm.org/doi/full/10.1056/ | "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1504720", | ||
"pageid" : | "pageid" : 2448, | ||
"pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/ | "pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa1504720", | ||
"trainingLevel" : " | "trainingLevel" : "intern", | ||
"citation" : " | "citation" : "Zinman B, <i>et al</i>. \"Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes\". <i>The New England Journal of Medicine</i>. 2015. 373(22):2117-28.", | ||
"subspecialties" : "Endocrinology", | "subspecialties" : "Cardiology;Endocrinology", | ||
"expansion" : " | "expansion" : "", | ||
"statusUsableDate" : " | "statusUsableDate" : "2015-10-01", | ||
"briefResultsDescription" : " | "briefResultsDescription" : "Empagliflozin reduces mortality compared to placebo in patients with type 2 diabetes", | ||
"published" : " | "published" : "2015-09-17", | ||
"pageName" : " | "pageName" : "EMPA-REG OUTCOME", | ||
"diseases" : "Diabetes Mellitus", | "diseases" : "Diabetes Mellitus", | ||
"abbreviation" : " | "abbreviation" : "EMPA-REG OUTCOME", | ||
"title" : " | "title" : "Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes", | ||
"pmid" : " | "pmid" : "26378978" | ||
}, | }, | ||
{ | { | ||
"timestamp" : " | "timestamp" : "2022-10-13T18:59:03Z", | ||
"briefDesignDescription" : " | "briefDesignDescription" : "Empagliflozin in HFmrEF and HFpEF", | ||
"fulltexturl" : " | "fulltexturl" : "https://www.nejm.org/doi/full/10.1056/NEJMoa2107038", | ||
"pageid" : | "pageid" : 4440, | ||
"pdfurl" : | "pdfurl" : null, | ||
"trainingLevel" : "Resident", | "trainingLevel" : "Resident", | ||
"citation" : " | "citation" : "Anker S, <i>et al</i>. \"Empagliflozin in Heart Failure with a Preserved Ejection Fraction\". <i>New England Journal of Medicine</i>. 2021. epub 2021-08-27:1-11.", | ||
"subspecialties" : "Cardiology", | "subspecialties" : "Cardiology", | ||
"expansion" : " | "expansion" : "Empagliflozin Outcome Trial in Patients with Chronic Heart Failure with Preserved Ejection Fraction", | ||
"statusUsableDate" : " | "statusUsableDate" : "2021-09-09", | ||
"briefResultsDescription" : " | "briefResultsDescription" : "Empagliflozin improved outcomes in HFpEF", | ||
"published" : " | "published" : "2021-08-27", | ||
"pageName" : " | "pageName" : "EMPEROR-Preserved", | ||
"diseases" : "Heart Failure", | "diseases" : "Heart Failure", | ||
"abbreviation" : " | "abbreviation" : "EMPEROR-Preserved", | ||
"title" : " | "title" : "Empagliflozin in Heart Failure with a Preserved Ejection Fraction", | ||
"pmid" : " | "pmid" : "34449189" | ||
}, | }, | ||
{ | { | ||
"timestamp" : " | "timestamp" : "2017-12-03T22:35:16Z", | ||
"briefDesignDescription" : " | "briefDesignDescription" : "Eplerenone in HFrEF", | ||
"fulltexturl" : "http:// | "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1009492", | ||
"pageid" : | "pageid" : 120, | ||
"pdfurl" : "", | "pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa1009492", | ||
"trainingLevel" : "Resident", | "trainingLevel" : "Resident", | ||
"citation" : " | "citation" : "Zannad F, <i>et al</i>. \"Eplerenone in patients with systolic heart failure and mild symptoms\". <i>The New England Journal of Medicine</i>. 2011. 364(1):11-21.", | ||
"subspecialties" : " | "subspecialties" : "Cardiology", | ||
"expansion" : " | "expansion" : "Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure", | ||
"statusUsableDate" : " | "statusUsableDate" : "2012-08-01", | ||
"briefResultsDescription" : " | "briefResultsDescription" : "Eplerenone reduces CV deaths and HF hospitalizations", | ||
"published" : " | "published" : "2011-01-06", | ||
"pageName" : " | "pageName" : "EMPHASIS-HF", | ||
"diseases" : " | "diseases" : "Heart Failure", | ||
"abbreviation" : " | "abbreviation" : "EMPHASIS-HF", | ||
"title" : " | "title" : "Eplerenone in patients with systolic heart failure and mild symptoms", | ||
"pmid" : " | "pmid" : "21073363" | ||
}, | }, | ||
{ | { | ||
"timestamp" : " | "timestamp" : "2024-10-03T18:39:58Z", | ||
"briefDesignDescription" : " | "briefDesignDescription" : "Edoxaban vs. warfarin in AF", | ||
"fulltexturl" : " | "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1310907", | ||
"pageid" : | "pageid" : 2471, | ||
"pdfurl" : " | "pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa1310907", | ||
"trainingLevel" : " | "trainingLevel" : "resident", | ||
"citation" : " | "citation" : "Guigliano RP, <i>et al</i>. \"Edoxaban versus warfarin in patients with atrial fibrillation\". <i>The New England Journal of Medicine</i>. 2013. 369(22):2093-2104.", | ||
"subspecialties" : "Cardiology", | "subspecialties" : "Cardiology", | ||
"expansion" : " | "expansion" : "Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation - Thrombolysis in Myocardial Infarction 48", | ||
"statusUsableDate" : " | "statusUsableDate" : "2017-02-01", | ||
"briefResultsDescription" : " | "briefResultsDescription" : "Edoxaban is noninferior to warfarin to prevent stroke or thromboembolism", | ||
"published" : " | "published" : "2013-11-28", | ||
"pageName" : " | "pageName" : "ENGAGE AF-TIMI 48", | ||
"diseases" : " | "diseases" : "Atrial Fibrillation", | ||
"abbreviation" : " | "abbreviation" : "ENGAGE AF-TIMI 48", | ||
"title" : " | "title" : "Edoxaban versus warfarin in patients with atrial fibrillation", | ||
"pmid" : " | "pmid" : "24251359" | ||
}, | }, | ||
{ | { | ||
"timestamp" : " | "timestamp" : "2019-04-18T17:47:16Z", | ||
"briefDesignDescription" : " | "briefDesignDescription" : "Aspirin vs. rivaroxaban for postoperative VTE prophylaxis", | ||
"fulltexturl" : "http://www.nejm.org/doi/full/10.1056/ | "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1712746", | ||
"pageid" : | "pageid" : 3552, | ||
"pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/ | "pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa1712746", | ||
"trainingLevel" : " | "trainingLevel" : "Resident", | ||
"citation" : " | "citation" : "Anderson DR, <i>et al</i>. \"Aspirin or Rivaroxaban for VTE Prophylaxis after Hip or Knee Arthroplasty\". <i>The New England Journal of Medicine</i>. 2018. 378(8):699-707.", | ||
"subspecialties" : " | "subspecialties" : "Orthopedics;Hematology", | ||
"expansion" : " | "expansion" : "Extended Venous Thromboembolism Prophylaxis Comparing Rivaroxaban to Aspirin Following Total Hip and Knee Arthroplasty II", | ||
"statusUsableDate" : " | "statusUsableDate" : "2018-03-29", | ||
"briefResultsDescription" : " | "briefResultsDescription" : "Aspirin similar to rivaroxaban for prevention of VTE", | ||
"published" : " | "published" : "2018-02-22", | ||
"pageName" : " | "pageName" : "EPCAT II", | ||
"diseases" : " | "diseases" : "Deep Vein Thrombosis;Hip Fracture;Meniscal Tear;Osteoarthritis;Pulmonary Embolism;Venous Thromboembolism", | ||
"abbreviation" : " | "abbreviation" : "EPCAT II", | ||
"title" : " | "title" : "Aspirin or Rivaroxaban for VTE Prophylaxis after Hip or Knee Arthroplasty", | ||
"pmid" : " | "pmid" : "29466159" | ||
}, | }, | ||
{ | { | ||
"timestamp" : " | "timestamp" : "2015-12-24T15:08:03Z", | ||
"briefDesignDescription" : " | "briefDesignDescription" : "Eplerenone post-MI with HFrEF", | ||
"fulltexturl" : "http://www.nejm.org/doi/full/10.1056/ | "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa030207", | ||
"pageid" : | "pageid" : 16, | ||
"pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/ | "pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa030207", | ||
"trainingLevel" : "Resident", | "trainingLevel" : "Resident", | ||
"citation" : " | "citation" : "Pitt B, <i>et al</i>. \"Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction\". <i>The New England Journal of Medicine</i>. 2003. 348(14):1309-21.", | ||
"subspecialties" : "Cardiology", | "subspecialties" : "Cardiology", | ||
"expansion" : " | "expansion" : "Eplerenone Post–Acute Myocardial Infarction Heart Failure Efficacy and Survival Study", | ||
"statusUsableDate" : "2012-03-01", | "statusUsableDate" : "2012-03-01", | ||
"briefResultsDescription" : " | "briefResultsDescription" : "Mortality benefit of eplerenone post MI with HFrEF", | ||
"published" : " | "published" : "2003-04-03", | ||
"pageName" : " | "pageName" : "EPHESUS", | ||
"diseases" : "Heart Failure", | "diseases" : "Heart Failure;Acute Coronary Syndrome;Myocardial Infarction", | ||
"abbreviation" : " | "abbreviation" : "EPHESUS", | ||
"title" : " | "title" : "Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction", | ||
"pmid" : " | "pmid" : "12668699" | ||
}, | }, | ||
{ | { | ||
"timestamp" : " | "timestamp" : "2024-10-03T19:17:59Z", | ||
"briefDesignDescription" : " | "briefDesignDescription" : "Edoxaban±antiplatelet in AF+stable CAD", | ||
"fulltexturl" : " | "fulltexturl" : "https://www.nejm.org/doi/10.1056/NEJMoa2407362", | ||
"pageid" : | "pageid" : 5576, | ||
"pdfurl" : " | "pdfurl" : "https://www.nejm.org/doi/pdf/10.1056/NEJMoa2407362", | ||
"trainingLevel" : " | "trainingLevel" : "resident", | ||
"citation" : " | "citation" : "Choo MS, <i>et al</i>. \"Edoxaban antithrombotic therapy for atrial fibrillation and stable coronary artery disease\". <i>The New England Journal of Medicine</i>. 2024. 1-13.", | ||
"subspecialties" : "Cardiology", | "subspecialties" : "Cardiology", | ||
"expansion" : " | "expansion" : "Edoxaban Versus Edoxaban With antiPlatelet Agent In Patients With Atrial Fibrillation and Chronic Stable Coronary Artery Disease", | ||
"statusUsableDate" : " | "statusUsableDate" : "2024-09-29", | ||
"briefResultsDescription" : " | "briefResultsDescription" : "Edoxaban monotherapy has lower bleeding events in AF+stable CAD", | ||
"published" : " | "published" : "2024-09-01", | ||
"pageName" : " | "pageName" : "EPIC-CAD", | ||
"diseases" : " | "diseases" : "Coronary Artery Disease;Atrial Fibrillation", | ||
"abbreviation" : " | "abbreviation" : "EPIC-CAD", | ||
"title" : " | "title" : "Edoxaban antithrombotic therapy for atrial fibrillation and stable coronary artery disease", | ||
"pmid" : " | "pmid" : "39225258" | ||
}, | }, | ||
{ | { | ||
"timestamp" : " | "timestamp" : "2017-12-03T22:35:20Z", | ||
"briefDesignDescription" : " | "briefDesignDescription" : "PSA for prostate cancer screening", | ||
"fulltexturl" : " | "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa0810084", | ||
"pageid" : | "pageid" : 2796, | ||
"pdfurl" : "", | "pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa0810084", | ||
"trainingLevel" : " | "trainingLevel" : "Intern", | ||
"citation" : " | "citation" : "Schröder FH, <i>et al</i>. \"Screening and Prostate-Cancer Mortality in a Randomized European Study\". <i>The New England Journal of Medicine</i>. 2009. 360(13):1320-1328.", | ||
"subspecialties" : " | "subspecialties" : "Urology;Oncology;Preventive Medicine", | ||
"expansion" : " | "expansion" : "European Randomized Study of Screening for Prostate Cancer", | ||
"statusUsableDate" : " | "statusUsableDate" : "2016-07-01", | ||
"briefResultsDescription" : " | "briefResultsDescription" : "Decrease in prostate cancer mortality but increased risk of overdiagnosis and overtreatment", | ||
"published" : " | "published" : "2009-07-09", | ||
"pageName" : " | "pageName" : "ERSPC", | ||
"diseases" : " | "diseases" : "Prostate Cancer", | ||
"abbreviation" : " | "abbreviation" : "ERSPC", | ||
"title" : " | "title" : "Screening and Prostate-Cancer Mortality in a Randomized European Study", | ||
"pmid" : " | "pmid" : "19297566" | ||
}, | }, | ||
{ | { | ||
"timestamp" : " | "timestamp" : "2017-12-03T22:35:21Z", | ||
"briefDesignDescription" : " | "briefDesignDescription" : "PA catheters in acute HF management", | ||
"fulltexturl" : | "fulltexturl" : null, | ||
"pageid" : | "pageid" : 1407, | ||
"pdfurl" : " | "pdfurl" : "http://jama.jamanetwork.com/data/Journals/JAMA/4994/JOC50108.pdf", | ||
"trainingLevel" : " | "trainingLevel" : "Resident", | ||
"citation" : " | "citation" : "Binanay C, <i>et al</i>. \"Evaluation study of congestive heart failure and pulmonary artery catheterization effectiveness\". <i>JAMA</i>. 2005. 294(13):1625-1633.", | ||
"subspecialties" : " | "subspecialties" : "Cardiology;Critical Care", | ||
"expansion" : " | "expansion" : "Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheterization Effectiveness", | ||
"statusUsableDate" : " | "statusUsableDate" : "2013-06-01", | ||
"briefResultsDescription" : " | "briefResultsDescription" : "Routine PA catheters no better than clinical assessment", | ||
"published" : " | "published" : "2005-10-05", | ||
"pageName" : " | "pageName" : "ESCAPE", | ||
"diseases" : " | "diseases" : "Heart Failure", | ||
"abbreviation" : " | "abbreviation" : "ESCAPE", | ||
"title" : " | "title" : "Evaluation study of congestive heart failure and pulmonary artery catheterization effectiveness", | ||
"pmid" : " | "pmid" : "16204662" | ||
}, | }, | ||
{ | { | ||
"timestamp" : " | "timestamp" : "2017-12-03T22:35:22Z", | ||
"briefDesignDescription" : " | "briefDesignDescription" : "ASA+dipyridamole in secondary stroke prevention", | ||
"fulltexturl" : " | "fulltexturl" : "http://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2806%2968734-5/fulltext", | ||
"pageid" : | "pageid" : 1726, | ||
"pdfurl" : " | "pdfurl" : "http://download.thelancet.com/pdfs/journals/lancet/PIIS0140673606687345.pdf", | ||
"trainingLevel" : " | "trainingLevel" : "Intern", | ||
"citation" : " | "citation" : "Halkes PH, <i>et al</i>. \"Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): Randomized controlled trial\". <i>The Lancet</i>. 2006. 367(9523):1665-1673.", | ||
"subspecialties" : " | "subspecialties" : "Neurology", | ||
"expansion" : " | "expansion" : "European/Australasian Stroke Prevention in Reversible Ischaemia Trial", | ||
"statusUsableDate" : " | "statusUsableDate" : "2013-11-01", | ||
"briefResultsDescription" : " | "briefResultsDescription" : "ASA+dipyridamole better than ASA for secondary stroke prevention", | ||
"published" : " | "published" : "2006-05-20", | ||
"pageName" : " | "pageName" : "ESPRIT", | ||
"diseases" : " | "diseases" : "Stroke;Transient Ischemic Attack", | ||
"abbreviation" : " | "abbreviation" : "ESPRIT", | ||
"title" : " | "title" : "Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): Randomized controlled trial", | ||
"pmid" : " | "pmid" : "16714187" | ||
}, | }, | ||
{ | { | ||
"timestamp" : " | "timestamp" : "2017-12-03T22:35:24Z", | ||
"briefDesignDescription" : " | "briefDesignDescription" : "LMWH vs. UFH in UA/NSTEMI", | ||
"fulltexturl" : "http://www.nejm.org/doi/full/10.1056/ | "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJM199708143370702", | ||
"pageid" : | "pageid" : 1443, | ||
"pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/ | "pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJM199708143370702", | ||
"trainingLevel" : "Intern", | "trainingLevel" : "Intern", | ||
"citation" : " | "citation" : "Cohen M, <i>et al</i>. \"A Comparison of Low-Molecular-Weight Heparin with Unfractionated Heparin for Unstable Coronary Artery Disease\". <i>The New England Journal of Medicine</i>. 1997. 337(7):447-452.", | ||
"subspecialties" : "Cardiology", | "subspecialties" : "Cardiology", | ||
"expansion" : " | "expansion" : "Efficacy and Safety of Subcutaneous Enoxaparin in Non–Q-Wave Coronary Events Study Group", | ||
"statusUsableDate" : "2013- | "statusUsableDate" : "2013-05-01", | ||
"briefResultsDescription" : " | "briefResultsDescription" : "LMWH reduces 14-day mortality, MI, or recurrent angina in UA/NSTEMI", | ||
"published" : " | "published" : "1997-08-14", | ||
"pageName" : " | "pageName" : "ESSENCE", | ||
"diseases" : " | "diseases" : "Acute Coronary Syndrome", | ||
"abbreviation" : " | "abbreviation" : "ESSENCE", | ||
"title" : " | "title" : "A Comparison of Low-Molecular-Weight Heparin with Unfractionated Heparin for Unstable Coronary Artery Disease", | ||
"pmid" : " | "pmid" : "9250846" | ||
}, | }, | ||
{ | { | ||
"timestamp" : " | "timestamp" : "2021-01-25T01:47:56Z", | ||
"briefDesignDescription" : " | "briefDesignDescription" : "Ticagrelor vs. clopidogrel in symptomatic PAD", | ||
"fulltexturl" : "http://www.nejm.org/doi/full/10.1056/ | "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1611688", | ||
"pageid" : | "pageid" : 2878, | ||
"pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/ | "pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa1611688", | ||
"trainingLevel" : " | "trainingLevel" : "Resident", | ||
"citation" : " | "citation" : "Hiatt WR <i>et al</i>. \"Ticagrelor versus clopidogrel in symptomatic peripheral artery disease\". <i>New Engl J Med</i>. 2017. 376(1):32-40.", | ||
"subspecialties" : " | "subspecialties" : "Cardiology", | ||
"expansion" : " | "expansion" : "Examining use of ticagrelor in peripheral artery disease", | ||
"statusUsableDate" : " | "statusUsableDate" : "2017-01-01", | ||
"briefResultsDescription" : " | "briefResultsDescription" : "Ticagrelor not superior to clopidogrel in symptomatic PAD", | ||
"published" : " | "published" : "2017-01-05", | ||
"pageName" : " | "pageName" : "EUCLID (Ticagrelor)", | ||
"diseases" : " | "diseases" : "Peripheral Vascular Disease", | ||
"abbreviation" : " | "abbreviation" : "EUCLID", | ||
"title" : " | "title" : "Ticagrelor versus clopidogrel in symptomatic peripheral artery disease", | ||
"pmid" : " | "pmid" : "27959717" | ||
}, | }, | ||
{ | { | ||
"timestamp" : " | "timestamp" : "2018-02-08T17:32:01Z", | ||
"briefDesignDescription" : " | "briefDesignDescription" : "Perindopril in patients with stable CAD", | ||
"fulltexturl" : "", | "fulltexturl" : "http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(03)14286-9/fulltext", | ||
"pageid" : | "pageid" : 2823, | ||
"pdfurl" : "http:// | "pdfurl" : "http://www.thelancet.com/pdfs/journals/lancet/PIIS0140-6736(03)14286-9.pdf", | ||
"trainingLevel" : " | "trainingLevel" : "intern", | ||
"citation" : " | "citation" : "Fox KM, <i>et al</i>. \"Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease\". <i>The Lancet</i>. 2003. 362(9386):782–788.", | ||
"subspecialties" : " | "subspecialties" : "Cardiology", | ||
"expansion" : "", | "expansion" : "European Trial on Reduction of Cardiac Events with Perindopril in Patients with Stable Coronary Artery Disease", | ||
"statusUsableDate" : " | "statusUsableDate" : "2018-02-08", | ||
"briefResultsDescription" : " | "briefResultsDescription" : "Perindopril reduces composite of CV mortality, MI, or cardiac arrest", | ||
"published" : " | "published" : "2003-09-06", | ||
"pageName" : " | "pageName" : "EUROPA", | ||
"diseases" : " | "diseases" : "Coronary Artery Disease", | ||
"abbreviation" : "", | "abbreviation" : "EUROPA", | ||
"title" : " | "title" : "Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease", | ||
"pmid" : " | "pmid" : "13678872" | ||
}, | }, | ||
{ | { | ||
"timestamp" : " | "timestamp" : "2017-12-03T22:35:34Z", | ||
"briefDesignDescription" : " | "briefDesignDescription" : "Dexamethasone in meningitis", | ||
"fulltexturl" : "http://www.nejm.org/doi/full/10.1056/ | "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa021334", | ||
"pageid" : | "pageid" : 306, | ||
"pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/ | "pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa021334", | ||
"trainingLevel" : " | "trainingLevel" : "Resident", | ||
"citation" : " | "citation" : "de Gans JD, <i>et al</i>. \"Dexamethasone in Adults with Bacterial Meningitis\". <i>The New England Journal of Medicine</i>. 2002. 347(20):1549-1556.", | ||
"subspecialties" : " | "subspecialties" : "Infectious Disease;Neurology", | ||
"expansion" : "", | "expansion" : "European Dexamethasone Study", | ||
"statusUsableDate" : " | "statusUsableDate" : "2012-04-01", | ||
"briefResultsDescription" : " | "briefResultsDescription" : "Dexamethasone reduces mortality in bacterial meningitis", | ||
"published" : " | "published" : "2002-11-14", | ||
"pageName" : " | "pageName" : "European Dexamethasone Study", | ||
"diseases" : " | "diseases" : "Meningitis", | ||
"abbreviation" : "", | "abbreviation" : "EDS", | ||
"title" : " | "title" : "Dexamethasone in Adults with Bacterial Meningitis", | ||
"pmid" : " | "pmid" : "12432041" | ||
}, | }, | ||
{ | { | ||
"timestamp" : "2017-12-03T22:35: | "timestamp" : "2017-12-03T22:35:27Z", | ||
"briefDesignDescription" : " | "briefDesignDescription" : "Tolvaptan in acute HF in HFrEF", | ||
"fulltexturl" : | "fulltexturl" : null, | ||
"pageid" : | "pageid" : 1345, | ||
"pdfurl" : "http:// | "pdfurl" : "http://jama.jamanetwork.com/data/Journals/JAMA/5131/joc70029_1319_1331.pdf", | ||
"trainingLevel" : " | "trainingLevel" : "Resident", | ||
"citation" : " | "citation" : "Konstam MA, <i>et al</i>. \"The Effects of Oral Tolvaptan in Patients Hospitalized for Worsening Heart Failure\". <i>The Journal of the American Medical Association</i>. 2007. 297(12):1319-1331.", | ||
"subspecialties" : " | "subspecialties" : "Cardiology", | ||
"expansion" : | "expansion" : "Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan", | ||
"statusUsableDate" : " | "statusUsableDate" : "2013-06-01", | ||
"briefResultsDescription" : " | "briefResultsDescription" : "No benefit from tolvaptan when given for 60 days after acute HF episode", | ||
"published" : " | "published" : "2007-03-28", | ||
"pageName" : " | "pageName" : "EVEREST-Outcomes", | ||
"diseases" : " | "diseases" : "Heart Failure", | ||
"abbreviation" : | "abbreviation" : "EVEREST", | ||
"title" : " | "title" : "The Effects of Oral Tolvaptan in Patients Hospitalized for Worsening Heart Failure", | ||
"pmid" : " | "pmid" : "17384437" | ||
}, | }, | ||
{ | { | ||
"timestamp" : " | "timestamp" : "2024-06-27T19:03:26Z", | ||
"briefDesignDescription" : " | "briefDesignDescription" : "TAVR in low-risk patients", | ||
"fulltexturl" : " | "fulltexturl" : "https://www.nejm.org/doi/full/10.1056/NEJMoa1816885", | ||
"pageid" : | "pageid" : 4061, | ||
"pdfurl" : " | "pdfurl" : "https://www.nejm.org/doi/pdf/10.1056/NEJMoa1816885", | ||
"trainingLevel" : " | "trainingLevel" : "resident", | ||
"citation" : " | "citation" : "Popma JJ, <i>et al</i>. \"Transcatheter aortic-valve replacement with a self-expanding valve in low-risk patients\". <i>The New England Journal of Medicine</i>. 2019. 380(18):1706-1715.", | ||
"subspecialties" : " | "subspecialties" : "Cardiology", | ||
"expansion" : "", | "expansion" : "", | ||
"statusUsableDate" : " | "statusUsableDate" : "2024-06-27", | ||
"briefResultsDescription" : " | "briefResultsDescription" : "TAVR non-inferior to surgery at 24 months in low-risk patients", | ||
"published" : " | "published" : "2019-05-02", | ||
"pageName" : " | "pageName" : "Evolut Low Risk", | ||
"diseases" : " | "diseases" : "Aortic Stenosis", | ||
"abbreviation" : " | "abbreviation" : "", | ||
"title" : " | "title" : "Transcatheter aortic-valve replacement with a self-expanding valve in low-risk patients", | ||
"pmid" : " | "pmid" : "30883053" | ||
}, | }, | ||
{ | { | ||
"timestamp" : " | "timestamp" : "2017-12-03T22:35:28Z", | ||
"briefDesignDescription" : " | "briefDesignDescription" : "Cinacalcet in ESRD", | ||
"fulltexturl" : " | "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1205624", | ||
"pageid" : | "pageid" : 2426, | ||
"pdfurl" : " | "pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa1205624", | ||
"trainingLevel" : "Resident", | "trainingLevel" : "Resident", | ||
"citation" : " | "citation" : "Chertow GM, <i>et al</i>. \"Effect of Cinacalcet on Cardiovascular Disease in Patients Undergoing Dialysis\". <i>The New England Journal of Medicine</i>. 2012. 367(26):2482-2494.", | ||
"subspecialties" : " | "subspecialties" : "Nephrology", | ||
"expansion" : " | "expansion" : "Effect of Cinacalcet on Cardiovascular Disease in Patients Undergoing Dialysis", | ||
"statusUsableDate" : " | "statusUsableDate" : "2015-10-01", | ||
"briefResultsDescription" : " | "briefResultsDescription" : "Cinecalcet did not reduce CV events in ESRD", | ||
"published" : " | "published" : "2012-12-27", | ||
"pageName" : " | "pageName" : "EVOLVE", | ||
"diseases" : " | "diseases" : "Chronic Kidney Disease;Cardiovascular Disease", | ||
"abbreviation" : " | "abbreviation" : "EVOLVE", | ||
"title" : " | "title" : "Effect of Cinacalcet on Cardiovascular Disease in Patients Undergoing Dialysis", | ||
"pmid" : " | "pmid" : "23121374" | ||
}, | }, | ||
{ | { | ||
"timestamp" : " | "timestamp" : "2017-12-03T22:35:29Z", | ||
"briefDesignDescription" : " | "briefDesignDescription" : "CABG vs. PCI in left main CAD", | ||
"fulltexturl" : "http://www.nejm.org/doi/full/10.1056/ | "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1610227", | ||
"pageid" : | "pageid" : 2868, | ||
"pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/ | "pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa1610227", | ||
"trainingLevel" : "Resident", | "trainingLevel" : "Resident", | ||
"citation" : " | "citation" : "Stone GW, <i>et al</i>. \"Everolimus-eluting stents or bypass surgery for left main coronary artery disease\". <i>The New England Journal of Medicine</i>. 2016. 375(23):2223-35.", | ||
"subspecialties" : "Cardiology | "subspecialties" : "Cardiology", | ||
"expansion" : " | "expansion" : "XIENCE versus Coronary Artery Bypass Surgery for Effectiveness of Left Main Revascularization (EXCEL)", | ||
"statusUsableDate" : " | "statusUsableDate" : "2016-12-01", | ||
"briefResultsDescription" : " | "briefResultsDescription" : "PCI noninferior to CABG in left main CAD with low-intermediate anatomic complexity", | ||
"published" : " | "published" : "2016-12-08", | ||
"pageName" : " | "pageName" : "EXCEL", | ||
"diseases" : " | "diseases" : "Coronary Artery Disease", | ||
"abbreviation" : " | "abbreviation" : "EXCEL", | ||
"title" : " | "title" : "Everolimus-eluting stents or bypass surgery for left main coronary artery disease", | ||
"pmid" : " | "pmid" : "27797291" | ||
}, | }, | ||
{ | { | ||
"timestamp" : " | "timestamp" : "2017-12-03T22:35:31Z", | ||
"briefDesignDescription" : " | "briefDesignDescription" : "Omalizumab in severe allergic asthma", | ||
"fulltexturl" : " | "fulltexturl" : null, | ||
"pageid" : | "pageid" : 1434, | ||
"pdfurl" : " | "pdfurl" : "http://annals.org/data/Journals/AIM/20231/0000605-201105030-00002.pdf", | ||
"trainingLevel" : "Fellow", | |||
"citation" : "Hanania NA, <i>et al</i>. \"Omalizumab in Severe Allergic Asthma Inadequately Controlled With Standard Therapy: A Randomized Trial\". <i>Annals of Internal Medicine</i>. 2011. 154(9):573-582.", | |||
"subspecialties" : "Allergy and Immunology;Pulmonology;Pediatrics", | |||
"expansion" : "A Study of Omalizumab/Xolair in Subjects With Moderate to Severe Persistent Asthma", | |||
"statusUsableDate" : "2013-10-01", | |||
"briefResultsDescription" : "Omalizumab reduces asthma exacerbations", | |||
"published" : "2011-05-03", | |||
"pageName" : "EXTRA", | |||
"diseases" : "Asthma", | |||
"abbreviation" : "EXTRA", | |||
"title" : "Omalizumab in Severe Allergic Asthma Inadequately Controlled With Standard Therapy: A Randomized Trial", | |||
"pmid" : "21536936" | |||
}, | |||
{ | |||
"timestamp" : "2015-11-07T23:16:22Z", | |||
"briefDesignDescription" : "Fluid management in ARDS", | |||
"fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa062200", | |||
"pageid" : 24, | |||
"pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa062200", | |||
"trainingLevel" : "Resident", | "trainingLevel" : "Resident", | ||
"citation" : " | "citation" : "Wiedemann HP, <i>et al</i>. \"Comparison of two fluid-management strategies in acute lung injury\". <i>The New England Journal of Medicine</i>. 2006. 354(24):2564-75.", | ||
"subspecialties" : " | "subspecialties" : "Critical Care", | ||
"expansion" : " | "expansion" : "Fluids and Catheters Treatment Trial", | ||
"statusUsableDate" : " | "statusUsableDate" : "2012-03-01", | ||
"briefResultsDescription" : " | "briefResultsDescription" : "Mortality benefit of conservative fluid management in ALI/ARDS", | ||
"published" : " | "published" : "2006-06-15", | ||
"pageName" : " | "pageName" : "FACTT", | ||
"diseases" : " | "diseases" : "Acute Respiratory Distress Syndrome", | ||
"abbreviation" : " | "abbreviation" : "FACTT", | ||
"title" : " | "title" : "Comparison of two fluid-management strategies in acute lung injury", | ||
"pmid" : " | "pmid" : "16714767" | ||
}, | }, | ||
{ | { | ||
"timestamp" : " | "timestamp" : "2019-02-28T18:37:32Z", | ||
"briefDesignDescription" : " | "briefDesignDescription" : "Parenteral iron in HFrEF with iron deficiency", | ||
"fulltexturl" : " | "fulltexturl" : "https://www.nejm.org/doi/10.1056/NEJMoa0908355", | ||
"pageid" : | "pageid" : 2691, | ||
"pdfurl" : " | "pdfurl" : "https://www.nejm.org/doi/pdf/10.1056/NEJMoa0908355", | ||
"trainingLevel" : "Intern", | "trainingLevel" : "Intern", | ||
"citation" : " | "citation" : "Anker SD, <i>et al</i>. \"Ferric Carboxymaltose in Patients with Heart Failure and Iron Deficiency\". <i>The New England Journal of Medicine</i>. 2009. 361(25):2436-48.", | ||
"subspecialties" : " | "subspecialties" : "Cardiology;Hematology", | ||
"expansion" : " | "expansion" : "IV Iron for Symptoms in Patients with HFrEF and Iron Deficiency", | ||
"statusUsableDate" : " | "statusUsableDate" : "2019-03-01", | ||
"briefResultsDescription" : " | "briefResultsDescription" : "IV iron improves HFrEF symptoms in patients with HFrEF and iron deficiency", | ||
"published" : " | "published" : "2009-12-17", | ||
"pageName" : " | "pageName" : "FAIR-HF", | ||
"diseases" : " | "diseases" : "Heart Failure;Iron Deficiency Anemia", | ||
"abbreviation" : " | "abbreviation" : "FAIR-HF", | ||
"title" : " | "title" : "Ferric Carboxymaltose in Patients with Heart Failure and Iron Deficiency", | ||
"pmid" : " | "pmid" : "19920054" | ||
}, | }, | ||
{ | { | ||
"timestamp" : " | "timestamp" : "2018-01-03T20:13:15Z", | ||
"briefDesignDescription" : " | "briefDesignDescription" : "FFR-guided PCI in stable CAD", | ||
"fulltexturl" : " | "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa0807611", | ||
"pageid" : | "pageid" : 998, | ||
"pdfurl" : " | "pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa0807611", | ||
"trainingLevel" : " | "trainingLevel" : "resident", | ||
"citation" : " | "citation" : "Tonino PAL, <i>et al</i>. \"Fractional Flow Reserve versus Angiography for Guiding Percutaneous Coronary Intervention\". <i>The New England Journal of Medicine</i>. 2009. 360(3):213-224.", | ||
"subspecialties" : " | "subspecialties" : "Cardiology", | ||
"expansion" : " | "expansion" : "Fractional Flow Reserve versus Angiography for Multivessel Evaluation", | ||
"statusUsableDate" : " | "statusUsableDate" : "2012-10-01", | ||
"briefResultsDescription" : " | "briefResultsDescription" : "FFR reduces composite of death, nonfatal MI, urgent revascularization", | ||
"published" : " | "published" : "2009-01-15", | ||
"pageName" : " | "pageName" : "FAME", | ||
"diseases" : " | "diseases" : "Coronary Artery Disease", | ||
"abbreviation" : " | "abbreviation" : "FAME", | ||
"title" : " | "title" : "Fractional Flow Reserve versus Angiography for Guiding Percutaneous Coronary Intervention", | ||
"pmid" : " | "pmid" : "19144937" | ||
}, | }, | ||
{ | { | ||
"timestamp" : " | "timestamp" : "2018-07-05T13:05:28Z", | ||
"briefDesignDescription" : " | "briefDesignDescription" : "FFR-guided PCI vs. OMT in CAD", | ||
"fulltexturl" : "http://www. | "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1205361", | ||
"pageid" : | "pageid" : 1003, | ||
"pdfurl" : "", | "pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa1205361", | ||
"trainingLevel" : " | "trainingLevel" : "Resident", | ||
"citation" : " | "citation" : "De Bruyne B, <i>et al</i>. \"Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease\". <i>The New England Journal of Medicine</i>. 2012. 367(11):991-1001.", | ||
"subspecialties" : " | "subspecialties" : "Cardiology", | ||
"expansion" : " | "expansion" : "FFR vs. Angiographyfor Multivessel Evaluation 2", | ||
"statusUsableDate" : " | "statusUsableDate" : "2012-11-01", | ||
"briefResultsDescription" : " | "briefResultsDescription" : "FFR-guided PCI reduces urgent revascularization", | ||
"published" : " | "published" : "2012-09-13", | ||
"pageName" : " | "pageName" : "FAME 2", | ||
"diseases" : " | "diseases" : "Coronary Artery Disease", | ||
"abbreviation" : " | "abbreviation" : "FAME 2", | ||
"title" : " | "title" : "Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease", | ||
"pmid" : " | "pmid" : "22924638" | ||
}, | }, | ||
{ | { | ||
"timestamp" : " | "timestamp" : "2017-12-03T22:35:38Z", | ||
"briefDesignDescription" : " | "briefDesignDescription" : "Fluid resuscitation in Sub-Saharan Africa", | ||
"fulltexturl" : "http://www.nejm.org/doi/full/10.1056/ | "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1101549", | ||
"pageid" : | "pageid" : 1860, | ||
"pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/ | "pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa1101549", | ||
"trainingLevel" : " | "trainingLevel" : "Resident", | ||
"citation" : " | "citation" : "Maitland K, <i>et al</i>. \"Mortality after fluid bolus in African children with severe infection\". <i>The New England Journal of Medicine</i>. 2011. 364(26):2483-2495.", | ||
"subspecialties" : " | "subspecialties" : "Pediatrics;Critical Care", | ||
"expansion" : " | "expansion" : "Fluid Expansion as Supportive Therapy", | ||
"statusUsableDate" : " | "statusUsableDate" : "2014-11-01", | ||
"briefResultsDescription" : " | "briefResultsDescription" : "Albumin and saline increase mortality when compared to no fluids in this patient population", | ||
"published" : " | "published" : "2011-06-30", | ||
"pageName" : " | "pageName" : "FEAST", | ||
"diseases" : " | "diseases" : "Shock", | ||
"abbreviation" : " | "abbreviation" : "FEAST", | ||
"title" : " | "title" : "Mortality after fluid bolus in African children with severe infection", | ||
"pmid" : " | "pmid" : "21615299" | ||
}, | }, | ||
{ | { | ||
"timestamp" : " | "timestamp" : "2013-10-07T20:50:13Z", | ||
"briefDesignDescription" : " | "briefDesignDescription" : "Fidaxomicin in C. difficile", | ||
"fulltexturl" : "http://www.nejm.org/doi/full/10.1056/ | "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa0910812", | ||
"pageid" : | "pageid" : 255, | ||
"pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/ | "pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa0910812", | ||
"trainingLevel" : "Resident", | "trainingLevel" : "Resident", | ||
"citation" : " | "citation" : "Louie TJ, <i>et al</i>. \"Fidaxomicin versus Vancomycin for Clostridium difficile Infection\". <i>The New England Journal of Medicine</i>. 2011. 365(5):422-431.", | ||
"subspecialties" : " | "subspecialties" : "Infectious Disease;Gastroenterology", | ||
"expansion" : | "expansion" : null, | ||
"statusUsableDate" : " | "statusUsableDate" : "2012-03-01", | ||
"briefResultsDescription" : " | "briefResultsDescription" : "Fidaxomicin noninferior to vancomycin for cure, and resulted in 45% fewer recurrences", | ||
"published" : " | "published" : "2011-02-03", | ||
"pageName" : " | "pageName" : "Fidaxomicin in C. difficile Diarrhea", | ||
"diseases" : " | "diseases" : "Clostridium difficile", | ||
"abbreviation" : | "abbreviation" : null, | ||
"title" : " | "title" : "Fidaxomicin versus Vancomycin for Clostridium difficile Infection", | ||
"pmid" : " | "pmid" : "21288078" | ||
}, | }, | ||
{ | { | ||
"timestamp" : " | "timestamp" : "2024-10-17T17:57:15Z", | ||
"briefDesignDescription" : " | "briefDesignDescription" : "Mineralocorticoid antagonist in CKD/T2DM", | ||
"fulltexturl" : " | "fulltexturl" : "https://www.nejm.org/doi/full/10.1056/NEJMoa2025845", | ||
"pageid" : | "pageid" : 4384, | ||
"pdfurl" : " | "pdfurl" : "https://www.nejm.org/doi/pdf/10.1056/NEJMoa2025845", | ||
"trainingLevel" : " | "trainingLevel" : "Resident", | ||
"citation" : " | "citation" : "Bakris GL, <i>et al</i>. \"Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes\". <i>The New England Journal of Medicine</i>. 2020. 383(23):2219-2229.", | ||
"subspecialties" : " | "subspecialties" : "Nephrology;Endocrinology", | ||
"expansion" : "", | "expansion" : "Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease", | ||
"statusUsableDate" : " | "statusUsableDate" : "2024-10-17", | ||
"briefResultsDescription" : " | "briefResultsDescription" : "Mineralocorticoid antagonist slows CKD progression", | ||
"published" : " | "published" : "2020-10-23", | ||
"pageName" : " | "pageName" : "FIDELIO-DKD", | ||
"diseases" : " | "diseases" : "Chronic Kidney Disease;Diabetes Mellitus", | ||
"abbreviation" : " | "abbreviation" : "FIDELIO-DKD", | ||
"title" : " | "title" : "Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes", | ||
"pmid" : " | "pmid" : "33264825" | ||
}, | }, | ||
{ | { | ||
"timestamp" : " | "timestamp" : "2017-12-03T22:35:39Z", | ||
"briefDesignDescription" : " | "briefDesignDescription" : "Cryoablation vs. RF ablation in pAF", | ||
"fulltexturl" : "http://www.nejm.org/doi/full/10.1056/ | "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1602014", | ||
"pageid" : | "pageid" : 2795, | ||
"pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/ | "pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa1602014", | ||
"trainingLevel" : "Resident", | "trainingLevel" : "Resident", | ||
"citation" : " | "citation" : "Kuck K, <i>et al</i>. \"Cryoballoon or radiofrequency ablation for paroxysmal atrial fibrillation\". <i>The New England Journal of Medicine</i>. 2016. 374(23):2235-45.", | ||
"subspecialties" : " | "subspecialties" : "Cardiology", | ||
"expansion" : " | "expansion" : "", | ||
"statusUsableDate" : " | "statusUsableDate" : "2016-07-01", | ||
"briefResultsDescription" : " | "briefResultsDescription" : "Cryoablation equivalent to RF ablation in pAF", | ||
"published" : " | "published" : "2016-06-09", | ||
"pageName" : " | "pageName" : "FIRE AND ICE", | ||
"diseases" : " | "diseases" : "Atrial Fibrillation", | ||
"abbreviation" : " | "abbreviation" : "FIRE AND ICE", | ||
"title" : " | "title" : "Cryoballoon or radiofrequency ablation for paroxysmal atrial fibrillation", | ||
"pmid" : " | "pmid" : "27042964" | ||
}, | }, | ||
{ | { | ||
"timestamp" : " | "timestamp" : "2017-12-03T22:35:41Z", | ||
"briefDesignDescription" : " | "briefDesignDescription" : "LABA+LAMA vs. LABA+ICS in COPD", | ||
"fulltexturl" : " | "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1516385", | ||
"pageid" : | "pageid" : 2871, | ||
"pdfurl" : " | "pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa1516385", | ||
"trainingLevel" : "Resident", | "trainingLevel" : "Resident", | ||
"citation" : " | "citation" : "Wedzicha JA, <i>et al</i>. \"Indacaterol-Glycopyrronium versus Salmeterol-Fluticasone for COPD\". <i>The New England Journal of Medicine</i>. 2016. 374(23):2222-2234.", | ||
"subspecialties" : " | "subspecialties" : "Pulmonology", | ||
"expansion" : " | "expansion" : "Effect of Indacaterol Glycopyronium Vs. Fluticasone Salmeterol on COPD Exacerbations", | ||
"statusUsableDate" : " | "statusUsableDate" : "2017-01-01", | ||
"briefResultsDescription" : " | "briefResultsDescription" : "LABA+LAMA reduces COPD exacerbations", | ||
"published" : " | "published" : "2016-06-09", | ||
"pageName" : " | "pageName" : "FLAME (COPD)", | ||
"diseases" : " | "diseases" : "Emphysema;Chronic Bronchitis;Chronic Obstructive Pulmonary Disease", | ||
"abbreviation" : " | "abbreviation" : "FLAME COPD", | ||
"title" : " | "title" : "Indacaterol-Glycopyrronium versus Salmeterol-Fluticasone for COPD", | ||
"pmid" : " | "pmid" : "27181606" | ||
}, | }, | ||
{ | { | ||
"timestamp" : " | "timestamp" : "2018-10-08T21:47:35Z", | ||
"briefDesignDescription" : " | "briefDesignDescription" : "SSRI after CVA for motor recovery", | ||
"fulltexturl" : "http:// | "fulltexturl" : "http://linkinghub.elsevier.com/retrieve/pii/S1474-4422(10)70314-8", | ||
"pageid" : | "pageid" : 2370, | ||
"pdfurl" : " | "pdfurl" : "", | ||
"trainingLevel" : " | "trainingLevel" : "Resident", | ||
"citation" : " | "citation" : "Chollet F, <i>et al</i>. \"Fluoxetine for motor recovery after acute ischaemic stroke (FLAME): a randomised placebo-controlled trial\". <i>The Lancet Neurology</i>. 2011. 10(2):123-130.", | ||
"subspecialties" : " | "subspecialties" : "Neurology", | ||
"expansion" : " | "expansion" : "Fluoxetine for Motor Recovery after Acute Ischaemic Stroke", | ||
"statusUsableDate" : " | "statusUsableDate" : "2015-08-01", | ||
"briefResultsDescription" : " | "briefResultsDescription" : "Early fluoxetine improved motor outcomes post stroke", | ||
"published" : " | "published" : "2011-02-01", | ||
"pageName" : " | "pageName" : "FLAME (Stroke)", | ||
"diseases" : " | "diseases" : "Stroke", | ||
"abbreviation" : " | "abbreviation" : "FLAME", | ||
"title" : " | "title" : "Fluoxetine for motor recovery after acute ischaemic stroke (FLAME): a randomised placebo-controlled trial", | ||
"pmid" : " | "pmid" : "21216670" | ||
}, | }, | ||
{ | { | ||
"timestamp" : " | "timestamp" : "2024-10-03T17:48:57Z", | ||
"briefDesignDescription" : " | "briefDesignDescription" : "High-flow oxygen in respiratory failure", | ||
"fulltexturl" : "http://www.nejm.org/doi/full/10.1056/ | "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1503326", | ||
"pageid" : | "pageid" : 2375, | ||
"pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/ | "pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa1503326", | ||
"trainingLevel" : " | "trainingLevel" : "Intern", | ||
"citation" : " | "citation" : "Frat JP, <i>et al</i>. \"High-flow oxygen through nasal cannula in acute hypoxemic respiratory failure\". <i>The New England Journal of Medicine</i>. 2015. 372(23):2185-2196.", | ||
"subspecialties" : " | "subspecialties" : "Pulmonology;Critical Care Medicine", | ||
"expansion" : "", | "expansion" : "", | ||
"statusUsableDate" : " | "statusUsableDate" : "2012-03-01", | ||
"briefResultsDescription" : " | "briefResultsDescription" : "High-flow oxygen therapy reduces intubation need", | ||
"published" : "2015- | "published" : "2015-06-04", | ||
"pageName" : " | "pageName" : "FLORALI", | ||
"diseases" : " | "diseases" : "Hypoxemic Respiratory Failure", | ||
"abbreviation" : " | "abbreviation" : "FLORALI", | ||
"title" : " | "title" : "High-flow oxygen through nasal cannula in acute hypoxemic respiratory failure", | ||
"pmid" : " | "pmid" : "25981908" | ||
}, | }, | ||
{ | { | ||
"timestamp" : " | "timestamp" : "2017-12-14T18:13:26Z", | ||
"briefDesignDescription" : " | "briefDesignDescription" : "Transfusion thresholds after hip surgery", | ||
"fulltexturl" : " | "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1012452", | ||
"pageid" : | "pageid" : 2985, | ||
"pdfurl" : | "pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa1012452", | ||
"trainingLevel" : "Resident", | "trainingLevel" : "Resident", | ||
"citation" : " | "citation" : "Carson JL, <i>et al</i>. \"Liberal or Restrictive Transfusion in High-Risk Patients after Hip Surgery\". <i>The New england Journal of Medicine</i>. 2011. 365(26):2453-62.", | ||
"subspecialties" : " | "subspecialties" : "Hematology;Surgery", | ||
"expansion" : " | "expansion" : "Transfusion Trigger Trial for Functional Outcomes in Cardiovascular Patients Undergoing Surgical Hip Fracture Repair", | ||
"statusUsableDate" : " | "statusUsableDate" : "2017-12-14", | ||
"briefResultsDescription" : " | "briefResultsDescription" : "Liberal transfusions no better than restrictive", | ||
"published" : " | "published" : "2011-12-29", | ||
"pageName" : " | "pageName" : "FOCUS", | ||
"diseases" : " | "diseases" : "Hip Fracture;Anemia", | ||
"abbreviation" : " | "abbreviation" : "FOCUS", | ||
"title" : " | "title" : "Liberal or Restrictive Transfusion in High-Risk Patients after Hip Surgery", | ||
"pmid" : " | "pmid" : "22168590" | ||
}, | }, | ||
{ | { | ||
"timestamp" : " | "timestamp" : "2020-11-05T18:42:16Z", | ||
"briefDesignDescription" : " | "briefDesignDescription" : "Evolocumab for CVD events if atherosclerotic disease", | ||
"fulltexturl" : "http://www.nejm.org/doi/full/10.1056/ | "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1615664", | ||
"pageid" : | "pageid" : 2891, | ||
"pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/ | "pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa1615664", | ||
"trainingLevel" : "Resident", | "trainingLevel" : "Resident", | ||
"citation" : " | "citation" : "Sabatine MS, <i>et al</i>. \"Evolocumab and clinical outcomes in patients with cardiovascular disease\". <i>The New England Journal of Medicine</i>. 2017. epub 2017-03-17:1-10.", | ||
"subspecialties" : "Cardiology", | "subspecialties" : "Cardiology", | ||
"expansion" : " | "expansion" : "Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk", | ||
"statusUsableDate" : " | "statusUsableDate" : "2017-03-01", | ||
"briefResultsDescription" : " | "briefResultsDescription" : "Evolocumab reduces CV events in patients with atherosclerotic disease", | ||
"published" : " | "published" : "2017-03-17", | ||
"pageName" : " | "pageName" : "FOURIER", | ||
"diseases" : " | "diseases" : "Coronary Artery Disease", | ||
"abbreviation" : " | "abbreviation" : "FOURIER", | ||
"title" : " | "title" : "Evolocumab and clinical outcomes in patients with cardiovascular disease", | ||
"pmid" : " | "pmid" : "28304224" | ||
}, | }, | ||
{ | { | ||
"timestamp" : " | "timestamp" : "2017-12-03T22:35:45Z", | ||
"briefDesignDescription" : " | "briefDesignDescription" : "CABG vs. PCI for CAD in T2DM", | ||
"fulltexturl" : "http://www.nejm.org/doi/full/10.1056/ | "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1211585", | ||
"pageid" : | "pageid" : 2314, | ||
"pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/ | "pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa1211585", | ||
"trainingLevel" : " | "trainingLevel" : "Resident", | ||
"citation" : " | "citation" : "Farkouh ME, <i>et al</i>. \"Strategies for multivessel revascularization in patients with diabetes\". <i>The New England Journal of Medicine</i>. 2012. 367(25):2375-2384.", | ||
"subspecialties" : "Cardiology", | "subspecialties" : "Cardiology;Endocrinology", | ||
"expansion" : " | "expansion" : "Future Revascularization Evaluation in Patients with Diabetes Mellitus: Optimal Management of Multivessel Disease", | ||
"statusUsableDate" : " | "statusUsableDate" : "2016-04-01", | ||
"briefResultsDescription" : " | "briefResultsDescription" : "CABG reduces death and revascularization rates but causes more strokes", | ||
"published" : " | "published" : "2012-12-20", | ||
"pageName" : " | "pageName" : "FREEDOM", | ||
"diseases" : " | "diseases" : "Coronary Artery Disease;Diabetes Mellitus", | ||
"abbreviation" : " | "abbreviation" : "FREEDOM", | ||
"title" : " | "title" : "Strategies for multivessel revascularization in patients with diabetes", | ||
"pmid" : " | "pmid" : "23121323" | ||
}, | }, | ||
{ | { | ||
"timestamp" : " | "timestamp" : "2021-06-01T13:47:49Z", | ||
"briefDesignDescription" : " | "briefDesignDescription" : "Early invasive strategy in UA/NSTEMI", | ||
"fulltexturl" : "http://www. | "fulltexturl" : "http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(99)07349-3/fulltext", | ||
"pageid" : | "pageid" : 2451, | ||
"pdfurl" : "http://www. | "pdfurl" : "http://www.thelancet.com/pdfs/journals/lancet/PIIS0140-6736(99)07349-3.pdf", | ||
"trainingLevel" : "Resident", | "trainingLevel" : "Resident", | ||
"citation" : " | "citation" : "FRISC Investigators. \"Invasive compared with non-invasive treatment in unstable coronary-artery disease: FRISC II prospective randomised multicentre study\". <i>The Lancet</i>. 1999. 354(9180):708-15.", | ||
"subspecialties" : " | "subspecialties" : "Cardiology", | ||
"expansion" : " | "expansion" : "FRagmin and Fast Revascularisation during InStability in Coronary artery disease-II", | ||
"statusUsableDate" : " | "statusUsableDate" : "2015-11-01", | ||
"briefResultsDescription" : " | "briefResultsDescription" : "Fewer recurrent MIs with early invasive strategy in high-risk patients", | ||
"published" : " | "published" : "1999-08-28", | ||
"pageName" : " | "pageName" : "FRISC-II", | ||
"diseases" : " | "diseases" : "Coronary Artery Disease;Myocardial Infarction;Acute Coronary Syndrome", | ||
"abbreviation" : " | "abbreviation" : "FRISC-II", | ||
"title" : " | "title" : "Invasive compared with non-invasive treatment in unstable coronary-artery disease: FRISC II prospective randomised multicentre study", | ||
"pmid" : " | "pmid" : "10475181" | ||
}, | }, | ||
{ | { | ||
"timestamp" : " | "timestamp" : "2017-12-03T22:35:49Z", | ||
"briefDesignDescription" : " | "briefDesignDescription" : "Risk factors for GI bleeds in ICU patients", | ||
"fulltexturl" : "http://www.nejm.org/doi/full/10.1056/ | "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJM199402103300601", | ||
"pageid" : | "pageid" : 391, | ||
"pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/ | "pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJM199402103300601", | ||
"trainingLevel" : "Intern", | |||
"citation" : "Cook DJ, <i>et al</i>. \"Risk factors for gastrointestinal bleeding in critically ill patients\". <i>The New England Journal of Medicine</i>. 1994. 330(6):337-381.", | |||
"subspecialties" : "Critical Care;Gastroenterology", | |||
"expansion" : null, | |||
"statusUsableDate" : "2013-10-01", | |||
"briefResultsDescription" : "Greatest risk for GI bleed with coagulopathy and mechanical ventilation", | |||
"published" : "1994-02-10", | |||
"pageName" : "GI bleeding in ICU patients", | |||
"diseases" : "Gastrointestinal Hemorrhage", | |||
"abbreviation" : null, | |||
"title" : "Risk factors for gastrointestinal bleeding in critically ill patients", | |||
"pmid" : "8284001" | |||
}, | |||
{ | |||
"timestamp" : "2014-09-24T22:28:37Z", | |||
"briefDesignDescription" : "Lisinopril in acute MI", | |||
"fulltexturl" : "http://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2894%2990232-1/abstract", | |||
"pageid" : 258, | |||
"pdfurl" : "", | |||
"trainingLevel" : "Resident", | "trainingLevel" : "Resident", | ||
"citation" : " | "citation" : "GISSI-3 Group. \"Effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction\". <i>The Lancet</i>. 1994. 343(8906):1115-22.", | ||
"subspecialties" : "Cardiology", | "subspecialties" : "Cardiology", | ||
"expansion" : " | "expansion" : "Gruppo Italiano per lo Studio della Sopravvivenza nell'infarto Miocardico", | ||
"statusUsableDate" : "2012-03-01", | "statusUsableDate" : "2012-03-01", | ||
"briefResultsDescription" : " | "briefResultsDescription" : "Lisinopril improves 6-week mortality", | ||
"published" : " | "published" : "1994-05-07", | ||
"pageName" : " | "pageName" : "GISSI-3", | ||
"diseases" : " | "diseases" : "Acute Coronary Syndrome;Myocardial Infarction", | ||
"abbreviation" : " | "abbreviation" : "GISSI-3", | ||
"title" : " | "title" : "Effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction", | ||
"pmid" : " | "pmid" : "7910229" | ||
}, | }, | ||
{ | { | ||
"timestamp" : " | "timestamp" : "2023-08-03T17:47:16Z", | ||
"briefDesignDescription" : " | "briefDesignDescription" : "PUFA in patients with heart failure", | ||
"fulltexturl" : " | "fulltexturl" : "http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(08)61239-8/fulltext", | ||
"pageid" : | "pageid" : 2824, | ||
"pdfurl" : " | "pdfurl" : "http://www.thelancet.com/pdfs/journals/lancet/PIIS0140-6736(08)61239-8.pdf", | ||
"trainingLevel" : " | "trainingLevel" : "intern", | ||
"citation" : " | "citation" : "Tavazzi L, <i>et al</i>. \"Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure\". <i>The Lancet</i>. 2008. 372(9645):1223-1230.", | ||
"subspecialties" : "Cardiology", | "subspecialties" : "Cardiology", | ||
"expansion" : " | "expansion" : "Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico (GISSI)-Prevenzione", | ||
"statusUsableDate" : " | "statusUsableDate" : "2023-07-31", | ||
"briefResultsDescription" : " | "briefResultsDescription" : "PUFA reduces all-cause mortality and admission for CV disease", | ||
"published" : " | "published" : "2008-10-04", | ||
"pageName" : " | "pageName" : "GISSI-HF", | ||
"diseases" : " | "diseases" : "Heart failure", | ||
"abbreviation" : " | "abbreviation" : "GISSI-HF", | ||
"title" : " | "title" : "Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure", | ||
"pmid" : " | "pmid" : "18757090" | ||
}, | }, | ||
{ | { | ||
"timestamp" : "2017-12-03T22:35: | "timestamp" : "2017-12-03T22:35:51Z", | ||
"briefDesignDescription" : " | "briefDesignDescription" : "tPA in ACS", | ||
"fulltexturl" : "http://www.nejm.org/doi/full/10.1056/ | "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJM199309023291001", | ||
"pageid" : | "pageid" : 2177, | ||
"pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/ | "pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJM199309023291001", | ||
"trainingLevel" : " | "trainingLevel" : "Student", | ||
"citation" : " | "citation" : "Topol E, <i>et al</i>. \"An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction\". <i>The New England Journal of Medicine</i>. 1993. 329(10):673-682.", | ||
"subspecialties" : " | "subspecialties" : "Cardiology", | ||
"expansion" : " | "expansion" : "Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries", | ||
"statusUsableDate" : " | "statusUsableDate" : "2014-09-01", | ||
"briefResultsDescription" : " | "briefResultsDescription" : "tPA reduces mortality in ACS", | ||
"published" : " | "published" : "1993-09-03", | ||
"pageName" : " | "pageName" : "GUSTO", | ||
"diseases" : " | "diseases" : "Myocardial Infarction;Acute Coronary Syndrome", | ||
"abbreviation" : " | "abbreviation" : "GUSTO", | ||
"title" : " | "title" : "An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction", | ||
"pmid" : " | "pmid" : "8204123" | ||
}, | }, | ||
{ | { | ||
"timestamp" : " | "timestamp" : "2024-08-25T20:47:09Z", | ||
"briefDesignDescription" : " | "briefDesignDescription" : "Hypothermia for cardiac arrest", | ||
"fulltexturl" : | "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/nejmoa012689", | ||
"pageid" : | "pageid" : 410, | ||
"pdfurl" : "http:// | "pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/nejmoa012689", | ||
"trainingLevel" : "Resident", | "trainingLevel" : "Resident", | ||
"citation" : " | "citation" : "Holzer M, <i>et al</i>. \"Mild Therapeutic Hypothermia to Improve the Neurologic Outcome After Cardiac Arrest\". <i>The New England Journal of Medicine</i>. 2002. 346(8):549-556.", | ||
"subspecialties" : "Cardiology | "subspecialties" : "Critical Care;Neurology;Cardiology", | ||
"expansion" : " | "expansion" : "Hypothermia After Cardiac Arrest", | ||
"statusUsableDate" : " | "statusUsableDate" : "2012-03-01", | ||
"briefResultsDescription" : " | "briefResultsDescription" : "Hypothermia improves neurologic outcomes and reduces mortality", | ||
"published" : " | "published" : "2002-02-21", | ||
"pageName" : " | "pageName" : "HACA", | ||
"diseases" : "Cardiac Arrest", | |||
"abbreviation" : "HACA", | |||
"title" : "Mild Therapeutic Hypothermia to Improve the Neurologic Outcome After Cardiac Arrest", | |||
"pmid" : "11856793" | |||
}, | |||
{ | |||
"timestamp" : "2017-12-03T22:35:53Z", | |||
"briefDesignDescription" : "Continuous-flow LVAD in heart failure", | |||
"fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa0909938#t", | |||
"pageid" : 2808, | |||
"pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa0909938", | |||
"trainingLevel" : "Fellow", | |||
"citation" : "Slaughter MS, <i>et al</i>. \"Advanced heart failure treated with continuous-flow left ventricular assist device\". <i>The New England Journal of Medicine</i>. 2009. 361(23):2241-2251.", | |||
"subspecialties" : "Cardiology", | |||
"expansion" : "Advanced heart failure treated with continuous-flow left ventricular assist device", | |||
"statusUsableDate" : "2016-09-01", | |||
"briefResultsDescription" : "Continuous-flow LVAD improved survival free from stroke and device failure", | |||
"published" : "2009-12-03", | |||
"pageName" : "HEARTMATE II", | |||
"diseases" : "Heart Failure", | "diseases" : "Heart Failure", | ||
"abbreviation" : " | "abbreviation" : "HEARTMATE II", | ||
"title" : " | "title" : "Advanced heart failure treated with continuous-flow left ventricular assist device", | ||
"pmid" : " | "pmid" : "19920051" | ||
}, | }, | ||
{ | { | ||
"timestamp" : " | "timestamp" : "2020-11-04T18:25:05Z", | ||
"briefDesignDescription" : " | "briefDesignDescription" : "Acetaminophen in febrile ICU patients", | ||
"fulltexturl" : "http://www. | "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1508375", | ||
"pageid" : | "pageid" : 2690, | ||
"pdfurl" : "http:// | "pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa1508375", | ||
"trainingLevel" : "Intern", | "trainingLevel" : "Intern", | ||
"citation" : " | "citation" : "Young P, <i>et al</i>. \"Acetaminophen for Fever in Critically Ill Patients with Suspected Infection\". <i>The New England Journal of Medicine</i>. 2015. 373(23):2215-2224.", | ||
"subspecialties" : " | "subspecialties" : "Critical Care;Infectious Disease", | ||
"expansion" : " | "expansion" : "Permissive Hyperthermia through Avoidance of Acetaminophen in Known or Suspected Infection in the Intensive Care Unit", | ||
"statusUsableDate" : " | "statusUsableDate" : "2017-09-01", | ||
"briefResultsDescription" : " | "briefResultsDescription" : "Acetaminophen does not improves ICU outcomes", | ||
"published" : " | "published" : "2015-12-03", | ||
"pageName" : " | "pageName" : "HEAT", | ||
"diseases" : " | "diseases" : "Sepsis;Fever", | ||
"abbreviation" : " | "abbreviation" : "HEAT", | ||
"title" : " | "title" : "Acetaminophen for Fever in Critically Ill Patients with Suspected Infection", | ||
"pmid" : " | "pmid" : "26436473" | ||
}, | }, | ||
{ | { | ||
"timestamp" : " | "timestamp" : "2023-02-02T19:36:38Z", | ||
"briefDesignDescription" : " | "briefDesignDescription" : "Heparin vs. bivalirudin in PCI", | ||
"fulltexturl" : "http:// | "fulltexturl" : "http://linkinghub.elsevier.com/retrieve/pii/S0140-6736(14)60924-7", | ||
"pageid" : | "pageid" : 2394, | ||
"pdfurl" : " | "pdfurl" : "", | ||
"trainingLevel" : " | "trainingLevel" : "Resident", | ||
"citation" : " | "citation" : "Shahzad A, <i>et al</i>. \"Unfractionated heparin versus bivalirudin in primary percutaneous coronary intervention (HEAT-PPCI): an open-label, single centre, randomised controlled trial.\". <i>The Lancet</i>. 2014. 384(9957):1849-1858.", | ||
"subspecialties" : "Cardiology", | "subspecialties" : "Cardiology", | ||
"expansion" : " | "expansion" : "", | ||
"statusUsableDate" : " | "statusUsableDate" : "2023-01-29", | ||
"briefResultsDescription" : " | "briefResultsDescription" : "Heparin better than bivalirudin for PCI", | ||
"published" : " | "published" : "2014-11-22", | ||
"pageName" : " | "pageName" : "HEAT-PPCI", | ||
"diseases" : " | "diseases" : "Coronary Artery Disease", | ||
"abbreviation" : " | "abbreviation" : "HEAT-PPCI", | ||
"title" : " | "title" : "Unfractionated heparin versus bivalirudin in primary percutaneous coronary intervention (HEAT-PPCI): an open-label, single centre, randomised controlled trial.", | ||
"pmid" : " | "pmid" : "25002178" | ||
}, | }, | ||
{ | { | ||
"timestamp" : " | "timestamp" : "2018-10-25T17:06:10Z", | ||
"briefDesignDescription" : " | "briefDesignDescription" : "High dialysis dose and high-flux membrane in hemodialysis", | ||
"fulltexturl" : "http://www.nejm.org/doi/full/10.1056/ | "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa021583", | ||
"pageid" : | "pageid" : 2771, | ||
"pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/ | "pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa021583", | ||
"trainingLevel" : " | "trainingLevel" : "Fellow", | ||
"citation" : " | "citation" : "Rose EA, <i>et al</i>. \"Effect of Dialysis Dose and Membrane Flux in Maintenance Hemodialysis\". <i>The New England Journal of Medicine</i>. 2002. 347(25):2020-2019.", | ||
"subspecialties" : " | "subspecialties" : "Nephrology", | ||
"expansion" : " | "expansion" : "Hemodialysis", | ||
"statusUsableDate" : " | "statusUsableDate" : "2018-03-15", | ||
"briefResultsDescription" : " | "briefResultsDescription" : "High dialysis dose and high-flux membrane did not reduce all-cause mortality", | ||
"published" : " | "published" : "2002-12-19", | ||
"pageName" : " | "pageName" : "HEMO", | ||
"diseases" : " | "diseases" : "Chronic Kidney Disease", | ||
"abbreviation" : " | "abbreviation" : "HEMO", | ||
"title" : " | "title" : "Effect of Dialysis Dose and Membrane Flux in Maintenance Hemodialysis", | ||
"pmid" : " | "pmid" : "12490682" | ||
}, | }, | ||
{ | { | ||
"timestamp" : " | "timestamp" : "2013-10-09T17:11:02Z", | ||
"briefDesignDescription" : "Trastuzumab in breast cancer", | |||
"fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa052306", | |||
"pageid" : 440, | |||
"pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa052306", | |||
"briefDesignDescription" : " | |||
"fulltexturl" : "http://www.nejm.org/doi/full/10.1056/ | |||
"pageid" : | |||
"pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/ | |||
"trainingLevel" : "Resident", | "trainingLevel" : "Resident", | ||
"citation" : " | "citation" : "Piccart-Gebhart MJ, <i>et al</i>. \"Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer\". <i>The New England Journal of Medicine</i>. 2005. 353(16):1659-72.", | ||
"subspecialties" : " | "subspecialties" : "Oncology", | ||
"expansion" : " | "expansion" : "Herceptin Adjuvant Trial", | ||
"statusUsableDate" : "2012- | "statusUsableDate" : "2012-03-01", | ||
"briefResultsDescription" : " | "briefResultsDescription" : "Trastuzumab improves survival", | ||
"published" : " | "published" : "2005-10-20", | ||
"pageName" : " | "pageName" : "HERA", | ||
"diseases" : " | "diseases" : "Breast Cancer", | ||
"abbreviation" : " | "abbreviation" : "HERA", | ||
"title" : " | "title" : "Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer", | ||
"pmid" : " | "pmid" : "16236737" | ||
}, | }, | ||
{ | { | ||
"timestamp" : " | "timestamp" : "2020-10-29T17:37:34Z", | ||
"briefDesignDescription" : " | "briefDesignDescription" : "Edoxaban vs. LMWH in cancer VTE", | ||
"fulltexturl" : | "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1711948", | ||
"pageid" : | "pageid" : 3509, | ||
"pdfurl" : "http:// | "pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa1711948", | ||
"trainingLevel" : "Resident", | "trainingLevel" : "Resident", | ||
"citation" : " | "citation" : "Raskob GE, <i>et al</i>. \"Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism\". <i>The New England Journal of Medicine</i>. 2018. 378(7):615-624.", | ||
"subspecialties" : " | "subspecialties" : "Hematology;Oncology", | ||
"expansion" : " | "expansion" : "", | ||
"statusUsableDate" : " | "statusUsableDate" : "2018-02-01", | ||
"briefResultsDescription" : " | "briefResultsDescription" : "Edoxaban noninferior to dalteparin in cancer VTE", | ||
"published" : " | "published" : "2018-02-15", | ||
"pageName" : " | "pageName" : "Hokusai-VTE", | ||
"diseases" : " | "diseases" : "Venous Thromboembolism;Pulmonary Embolism;Deep Vein Thrombosis", | ||
"abbreviation" : " | "abbreviation" : "", | ||
"title" : " | "title" : "Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism", | ||
"pmid" : " | "pmid" : "29231094" | ||
}, | }, | ||
{ | { | ||
"timestamp" : " | "timestamp" : "2013-08-15T18:50:04Z", | ||
"briefDesignDescription" : " | "briefDesignDescription" : "Ramipril in patients with high CV risk", | ||
"fulltexturl" : " | "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJM200001203420301", | ||
"pageid" : | "pageid" : 1165, | ||
"pdfurl" : " | "pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJM200001203420301", | ||
"trainingLevel" : " | "trainingLevel" : "intern", | ||
"citation" : " | "citation" : "Yusuf S, <i>et al</i>. \"Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients\". <i>The New England Journal of Medicine</i>. 2000. 342(3):145-153.", | ||
"subspecialties" : "Cardiology", | "subspecialties" : "Cardiology;Neurology", | ||
"expansion" : "", | "expansion" : "Heart Outcomes Prevention Evaluation", | ||
"statusUsableDate" : " | "statusUsableDate" : "2012-03-01", | ||
"briefResultsDescription" : " | "briefResultsDescription" : "Ramipril reduces death, MI, and stroke", | ||
"published" : " | "published" : "2000-01-20", | ||
"pageName" : " | "pageName" : "HOPE", | ||
"diseases" : " | "diseases" : "Coronary Artery Disease;Stroke;Transient Ischemic Attack", | ||
"abbreviation" : "", | "abbreviation" : "HOPE", | ||
"title" : " | "title" : "Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients", | ||
"pmid" : " | "pmid" : "10639539" | ||
}, | }, | ||
{ | { | ||
"timestamp" : " | "timestamp" : "2020-12-31T20:42:03Z", | ||
"briefDesignDescription" : " | "briefDesignDescription" : "Voxelotor in sickle cell disease", | ||
"fulltexturl" : " | "fulltexturl" : "https://www.nejm.org/doi/full/10.1056/nejmoa1903212", | ||
"pageid" : | "pageid" : 4382, | ||
"pdfurl" : " | "pdfurl" : "https://www.nejm.org/doi/pdf/10.1056/NEJMoa1903212", | ||
"trainingLevel" : " | "trainingLevel" : "resident", | ||
"citation" : " | "citation" : "Vichinsky E, <i>et al</i>. \"A phase 3 randomized trial of voxelotor in sickle cell disease\". <i>The New England Journal of Medicine</i>. 2019. 381(8):509-519.", | ||
"subspecialties" : " | "subspecialties" : "Hematology", | ||
"expansion" : " | "expansion" : "Hemoglobin Oxygen Affinity Modulation to Inhibit HbS Polymerization", | ||
"statusUsableDate" : " | "statusUsableDate" : "2020-12-10", | ||
"briefResultsDescription" : " | "briefResultsDescription" : "Voxelotor increases hemoglobin and reduces evidence of hemolysis", | ||
"published" : " | "published" : "2019-08-08", | ||
"pageName" : " | "pageName" : "HOPE (Sickle Cell Disease)", | ||
"diseases" : " | "diseases" : "Sickle Cell Disease", | ||
"abbreviation" : " | "abbreviation" : "HOPE", | ||
"title" : " | "title" : "A phase 3 randomized trial of voxelotor in sickle cell disease", | ||
"pmid" : " | "pmid" : "31199090" | ||
}, | }, | ||
{ | { | ||
"timestamp" : " | "timestamp" : "2019-09-20T14:01:16Z", | ||
"briefDesignDescription" : " | "briefDesignDescription" : "Statin, BP meds, both, or neither for CVD 1° prevention", | ||
"fulltexturl" : "http://www.nejm.org/doi/full/10.1056/ | "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1600177", | ||
"pageid" : | "pageid" : 2770, | ||
"pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/ | "pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa1600177", | ||
"trainingLevel" : "Resident", | "trainingLevel" : "Resident", | ||
"citation" : " | "citation" : "Yusuf S, <i>et al</i>. \"Blood-Pressure and Cholesterol Lowering in Persons without Cardiovascular Disease\". <i>The New England Journal of Medicine</i>. 2016. 374(21):2032-2343.", | ||
"subspecialties" : "Cardiology", | "subspecialties" : "Cardiology", | ||
"expansion" : " | "expansion" : "Heart Outcomes Prevention Evaluation-3", | ||
"statusUsableDate" : " | "statusUsableDate" : "2019-09-19", | ||
"briefResultsDescription" : " | "briefResultsDescription" : "Statins lower events but BP meds don't.", | ||
"published" : "2016- | "published" : "2016-05-26", | ||
"pageName" : " | "pageName" : "HOPE-3", | ||
"diseases" : " | "diseases" : "Cardiovascular Disease", | ||
"abbreviation" : " | "abbreviation" : "HOPE-3", | ||
"title" : " | "title" : "Blood-Pressure and Cholesterol Lowering in Persons without Cardiovascular Disease", | ||
"pmid" : " | "pmid" : "27039945" | ||
}, | }, | ||
{ | { | ||
"timestamp" : " | "timestamp" : "2021-09-09T17:34:24Z", | ||
"briefDesignDescription" : " | "briefDesignDescription" : "Zoledronate vs. placebo in osteoporosis", | ||
"fulltexturl" : | "fulltexturl" : "https://www.nejm.org/doi/full/10.1056/NEJMoa067312", | ||
"pageid" : | "pageid" : 2765, | ||
"pdfurl" : " | "pdfurl" : "https://www.nejm.org/doi/pdf/10.1056/NEJMoa067312", | ||
"trainingLevel" : " | "trainingLevel" : "Resident", | ||
"citation" : " | "citation" : "Black DM, <i>et al</i>. \"Once-Yearly Zoledronic Acid for Treatment of Postmenopausal Osteoporosis\". <i>The New England Journal of Medicine</i>. 2007. 356(18):1809-22.", | ||
"subspecialties" : " | "subspecialties" : "Endocrinology;Preventive Medicine", | ||
"expansion" : " | "expansion" : "Health Outcomes and Reduced Incidence with Zoledronic Acid Once Yearly - Pivotal Fracture Trial", | ||
"statusUsableDate" : " | "statusUsableDate" : "2021-08-31", | ||
"briefResultsDescription" : " | "briefResultsDescription" : "Annual zoledronate reduces fracture risk in osteoporosis", | ||
"published" : " | "published" : "2007-05-03", | ||
"pageName" : " | "pageName" : "HORIZON-PFT", | ||
"diseases" : " | "diseases" : "Osteoporosis", | ||
"abbreviation" : " | "abbreviation" : "HORIZON-PFT", | ||
"title" : " | "title" : "Once-Yearly Zoledronic Acid for Treatment of Postmenopausal Osteoporosis", | ||
"pmid" : " | "pmid" : "17476007" | ||
}, | }, | ||
{ | { | ||
"timestamp" : " | "timestamp" : "2024-05-02T17:49:17Z", | ||
"briefDesignDescription" : " | "briefDesignDescription" : "Duration of empiric antibiotics in ↑risk neutropenic fever", | ||
"fulltexturl" : " | "fulltexturl" : "https://doi.org/10.1016/S2352-3026(17)30211-9", | ||
"pageid" : | "pageid" : 4119, | ||
"pdfurl" : | "pdfurl" : null, | ||
"trainingLevel" : " | "trainingLevel" : "Fellow", | ||
"citation" : " | "citation" : "Aguilar-Guisado M, <i>et al</i>. \"Optimisation of empirical antimicrobial therapy in patients with haematological malignancies and febrile neutropenia (How Long study): an open-label, randomised, controlled phase 4 trial\". <i>Lancet Haematology</i>. 2017. 4(12):e573-e583.", | ||
"subspecialties" : " | "subspecialties" : "Infectious Disease;Hematology", | ||
"expansion" : | "expansion" : null, | ||
"statusUsableDate" : " | "statusUsableDate" : "2021-03-15", | ||
"briefResultsDescription" : " | "briefResultsDescription" : "Shorter courses of antibiotics led to fewer days of antibiotics without excess harm", | ||
"published" : " | "published" : "2017-11-15", | ||
"pageName" : " | "pageName" : "How Long", | ||
"diseases" : " | "diseases" : "Febrile Neutropenia", | ||
"abbreviation" : | "abbreviation" : null, | ||
"title" : " | "title" : "Optimisation of empirical antimicrobial therapy in patients with haematological malignancies and febrile neutropenia (How Long study): an open-label, randomised, controlled phase 4 trial", | ||
"pmid" : " | "pmid" : "29153975" | ||
}, | }, | ||
{ | { | ||
"timestamp" : " | "timestamp" : "2020-02-06T19:36:49Z", | ||
"briefDesignDescription" : " | "briefDesignDescription" : "Simvastatin in high risk for CVD", | ||
"fulltexturl" : " | "fulltexturl" : "http://linkinghub.elsevier.com/retrieve/pii/S0140-6736(02)09327-3", | ||
"pageid" : | "pageid" : 2696, | ||
"pdfurl" : " | "pdfurl" : "", | ||
"trainingLevel" : " | "trainingLevel" : "Student", | ||
"citation" : " | "citation" : "Heart Protection Study Collaborative Group Writers. \"MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial\". <i>The Lancet</i>. 2002. 360(9326):7-22.", | ||
"subspecialties" : "Cardiology | "subspecialties" : "Cardiology", | ||
"expansion" : " | "expansion" : "Heart Protection Study Statin Arm", | ||
"statusUsableDate" : " | "statusUsableDate" : "2020-02-07", | ||
"briefResultsDescription" : " | "briefResultsDescription" : "Simvastatin reduces CVD events and death", | ||
"published" : " | "published" : "2002-06-06", | ||
"pageName" : " | "pageName" : "HPS Statin", | ||
"diseases" : " | "diseases" : "Hyperlipidemia;Cardiovascular Disease", | ||
"abbreviation" : " | "abbreviation" : "HPS", | ||
"title" : " | "title" : "MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial", | ||
"pmid" : " | "pmid" : "12114036" | ||
}, | }, | ||
{ | { | ||
"timestamp" : " | "timestamp" : "2017-12-03T22:35:56Z", | ||
"briefDesignDescription" : " | "briefDesignDescription" : "Niacin in atherosclerotic disease", | ||
"fulltexturl" : "http://www.nejm.org/doi/full/10.1056/ | "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1300955", | ||
"pageid" : | "pageid" : 2329, | ||
"pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/ | "pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa1300955", | ||
"trainingLevel" : " | "trainingLevel" : "Intern", | ||
"citation" : " | "citation" : "Landray MJ <i>et al</i>. \"Effects of extended-release niacin with laropiprant in high-risk patients\". <i>The New England Journal of Medicine</i>. 2014. 371(3):203-212.", | ||
"subspecialties" : "Cardiology", | "subspecialties" : "Cardiology", | ||
"expansion" : " | "expansion" : "Heart Protection Study 2-Treatment of HDL to Reduce the Incidence of Vascular Events", | ||
"statusUsableDate" : " | "statusUsableDate" : "2015-02-01", | ||
"briefResultsDescription" : " | "briefResultsDescription" : "Niacin is poorly tolerated, doesn't reduce major vascular events", | ||
"published" : " | "published" : "2014-07-17", | ||
"pageName" : " | "pageName" : "HPS2-THRIVE", | ||
"diseases" : "Coronary Artery Disease", | "diseases" : "Coronary Artery Disease;Peripheral Vascular Disease", | ||
"abbreviation" : " | "abbreviation" : "HPS2-THRIVE", | ||
"title" : " | "title" : "Effects of extended-release niacin with laropiprant in high-risk patients", | ||
"pmid" : " | "pmid" : "25014686" | ||
}, | }, | ||
{ | { | ||
"timestamp" : " | "timestamp" : "2017-12-03T22:35:58Z", | ||
"briefDesignDescription" : " | "briefDesignDescription" : "Early ART in HIV", | ||
"fulltexturl" : "http://www.nejm.org/doi/full/10.1056/ | "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1105243", | ||
"pageid" : | "pageid" : 1010, | ||
"pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/ | "pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa1105243", | ||
"trainingLevel" : "Resident", | "trainingLevel" : "Resident", | ||
"citation" : " | "citation" : "Cohen MS, <i>et al</i>. \"Prevention of HIV-1 Infection with Early Antiretroviral Therapy\". <i>The New England Journal of Medicine</i>. 2011. 365(6):493-505.", | ||
"subspecialties" : " | "subspecialties" : "Infectious Disease", | ||
"expansion" : " | "expansion" : "HIV Prevention Trials Network 052 Study", | ||
"statusUsableDate" : "2012- | "statusUsableDate" : "2012-10-01", | ||
"briefResultsDescription" : " | "briefResultsDescription" : "Reduced morbidity and HIV transmission", | ||
"published" : " | "published" : "2011-08-11", | ||
"pageName" : " | "pageName" : "HPTN 052", | ||
"diseases" : " | "diseases" : "HIV", | ||
"abbreviation" : " | "abbreviation" : "HPTN 052", | ||
"title" : " | "title" : "Prevention of HIV-1 Infection with Early Antiretroviral Therapy", | ||
"pmid" : " | "pmid" : "21767103" | ||
}, | }, | ||
{ | { | ||
"timestamp" : "2017-12-03T22:35: | "timestamp" : "2017-12-03T22:35:59Z", | ||
"briefDesignDescription" : " | "briefDesignDescription" : "High sensitivity troponin for acute chest pain", | ||
"fulltexturl" : "http://www. | "fulltexturl" : "http://www.sciencedirect.com/science/article/pii/S0735109714017264", | ||
"pageid" : | "pageid" : 2343, | ||
"pdfurl" : | "pdfurl" : null, | ||
"trainingLevel" : " | "trainingLevel" : "Intern", | ||
"citation" : " | "citation" : "Bandstein N, <i>et al</i>. \"Undetectable high-sensitivity cardiac troponin T level in the emergency department and risk of myocardial infarction\". <i>Journal of the American College of Cardiology</i>. 2014. 63(23):2569-2578.", | ||
"subspecialties" : " | "subspecialties" : "Emergency Medicine;Cardiology", | ||
"expansion" : | "expansion" : null, | ||
"statusUsableDate" : " | "statusUsableDate" : "2015-03-01", | ||
"briefResultsDescription" : " | "briefResultsDescription" : "HS troponin-T is associated with high NPV for MI at 30 days", | ||
"published" : " | "published" : "2014-06-17", | ||
"pageName" : " | "pageName" : "HS troponin-T to rule out MI", | ||
"diseases" : " | "diseases" : "Acute Coronary Syndrome;Myocardial Infarction", | ||
"abbreviation" : | "abbreviation" : null, | ||
"title" : " | "title" : "Undetectable high-sensitivity cardiac troponin T level in the emergency department and risk of myocardial infarction", | ||
"pmid" : " | "pmid" : "24694529" | ||
}, | }, | ||
{ | { | ||
"timestamp" : " | "timestamp" : "2017-12-03T22:36:04Z", | ||
"briefDesignDescription" : " | "briefDesignDescription" : "Perinatal vitamins to prevent neural tube defects", | ||
"fulltexturl" : "http://www.nejm.org/doi/full/10.1056/ | "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJM199212243272602", | ||
"pageid" : | "pageid" : 2142, | ||
"pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/ | "pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJM199212243272602", | ||
"trainingLevel" : " | "trainingLevel" : "Student", | ||
"citation" : " | "citation" : "Czeizel AE and Dudas I. \"Prevention of the first occurrence of neural-tube defects by periconceptional vitamin supplementation\". <i>The New England Journal of Medicine</i>. 1992. 327(26):1832-1835.", | ||
"subspecialties" : " | "subspecialties" : "Obstetrics;Preventive Medicine", | ||
"expansion" : null, | "expansion" : null, | ||
"statusUsableDate" : " | "statusUsableDate" : "2014-09-01", | ||
"briefResultsDescription" : " | "briefResultsDescription" : "Perinatal vitamins reduce neural tube defects", | ||
"published" : " | "published" : "1992-12-24", | ||
"pageName" : " | "pageName" : "Hungarian Prenatal Vitamin Trial", | ||
"diseases" : " | "diseases" : "Neural Tube Defects", | ||
"abbreviation" : null, | "abbreviation" : null, | ||
"title" : " | "title" : "Prevention of the first occurrence of neural-tube defects by periconceptional vitamin supplementation", | ||
"pmid" : " | "pmid" : "1307234" | ||
}, | }, | ||
{ | { | ||
"timestamp" : " | "timestamp" : "2023-11-22T21:12:44Z", | ||
"briefDesignDescription" : " | "briefDesignDescription" : "Hydrocortisone, Vit C, and thiamine in sepsis", | ||
"fulltexturl" : " | "fulltexturl" : "http://journal.chestnet.org/article/S0012-3692(16)62564-3/fulltext", | ||
"pageid" : | "pageid" : 2946, | ||
"pdfurl" : " | "pdfurl" : "http://journal.chestnet.org/article/S0012-3692(16)62564-3/pdf", | ||
"trainingLevel" : "Resident", | "trainingLevel" : "Resident", | ||
"citation" : " | "citation" : "Marik PE, <i>et al</i>. \"Hydrocortisone, Vitamin C, and Thiamine for the Treatment of Severe Sepsis and Septic Shock A Retrospective Before-After Study\". <i>Chest</i>. 2017. 151(6):1229-1238.", | ||
"subspecialties" : " | "subspecialties" : "Critical Care;Infectious Disease;Pulmonology", | ||
"expansion" : " | "expansion" : "", | ||
"statusUsableDate" : " | "statusUsableDate" : "2018-08-13", | ||
"briefResultsDescription" : " | "briefResultsDescription" : "Pilot study with impressive findings, low-quality data", | ||
"published" : " | "published" : "2017-06-01", | ||
"pageName" : " | "pageName" : "Hydrocortisone, Vitamin C, and Thiamine in Severe Sepsis and Septic Shock", | ||
"diseases" : " | "diseases" : "Sepsis;Shock", | ||
"abbreviation" : " | "abbreviation" : "", | ||
"title" : " | "title" : "Hydrocortisone, Vitamin C, and Thiamine for the Treatment of Severe Sepsis and Septic Shock A Retrospective Before-After Study", | ||
"pmid" : " | "pmid" : "27940189" | ||
}, | }, | ||
{ | { | ||
"timestamp" : " | "timestamp" : "2018-02-08T17:14:46Z", | ||
"briefDesignDescription" : " | "briefDesignDescription" : "Hydrocortisone in severe sepsis", | ||
"fulltexturl" : "http://www.nejm.org/doi/full/10.1056/ | "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMsa1410639", | ||
"pageid" : | "pageid" : 2860, | ||
"pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/ | "pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMsa1410639", | ||
"trainingLevel" : "Resident", | "trainingLevel" : "Resident", | ||
"citation" : " | "citation" : "Keh D, <i>et al</i>. \"Effect of hydrocortisone on development of shock among patients with severe sepsis\". <i>Journal of the American Medical Association</i>. 2016. 316(17):1775-1785.", | ||
"subspecialties" : " | "subspecialties" : "Critical Care", | ||
"expansion" : "", | "expansion" : "", | ||
"statusUsableDate" : "2016- | "statusUsableDate" : "2016-11-01", | ||
"briefResultsDescription" : " | "briefResultsDescription" : "Hydrocortisone not superior to placebo in severe sepsis", | ||
"published" : "2016- | "published" : "2016-10-03", | ||
"pageName" : " | "pageName" : "HYPRESS", | ||
"diseases" : " | "diseases" : "Sepsis", | ||
"abbreviation" : " | "abbreviation" : "HYPRESS", | ||
"title" : " | "title" : "Effect of hydrocortisone on development of shock among patients with severe sepsis", | ||
"pmid" : " | "pmid" : "27695824" | ||
}, | }, | ||
{ | { | ||
"timestamp" : " | "timestamp" : "2018-01-11T18:14:28Z", | ||
"briefDesignDescription" : " | "briefDesignDescription" : "Elderly HTN treatment", | ||
"fulltexturl" : "http://www.nejm.org/doi/full/10.1056/ | "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa0801369", | ||
"pageid" : | "pageid" : 2349, | ||
"pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/ | "pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa0801369", | ||
"trainingLevel" : " | "trainingLevel" : "Intern", | ||
"citation" : " | "citation" : "Beckett NS, <i>et al</i>. \"Treatment of hypertension in patients 80 years of age or older\". <i>The New England Journal of Medicine</i>. 2008. 358(18):1887-1898.", | ||
"subspecialties" : " | "subspecialties" : "Nephrology;Cardiology;Geriatrics", | ||
"expansion" : " | "expansion" : "Hypertension in the Very Elderly Trial", | ||
"statusUsableDate" : " | "statusUsableDate" : "2015-04-01", | ||
"briefResultsDescription" : " | "briefResultsDescription" : "Trend towards reduction in stroke with treatment (P", | ||
"published" : " | "published" : "2008-05-01", | ||
"pageName" : " | "pageName" : "HYVET", | ||
"diseases" : " | "diseases" : "Hypertension", | ||
"abbreviation" : " | "abbreviation" : "HYVET", | ||
"title" : " | "title" : "Treatment of hypertension in patients 80 years of age or older", | ||
"pmid" : " | "pmid" : "18378519" | ||
}, | }, | ||
{ | { | ||
"timestamp" : " | "timestamp" : "2017-09-24T13:54:35Z", | ||
"briefDesignDescription" : " | "briefDesignDescription" : "IABP in MI and cardiogenic shock", | ||
"fulltexturl" : "http:// | "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1208410", | ||
"pageid" : | "pageid" : 1065, | ||
"pdfurl" : "", | "pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa1208410", | ||
"trainingLevel" : " | "trainingLevel" : "Fellow", | ||
"citation" : " | "citation" : "Thiele H, <i>et al</i>. \"Intraaortic Balloon Support for Myocardial Infarction with Cardiogenic Shock\". <i>The New England Journal of Medicine</i>. 2012. 367(14):1287-1296.", | ||
"subspecialties" : " | "subspecialties" : "Cardiology;Critical Care", | ||
"expansion" : " | "expansion" : "Intraaortic Balloon Pump in Cardiogenic Shock II", | ||
"statusUsableDate" : " | "statusUsableDate" : "2012-03-01", | ||
"briefResultsDescription" : " | "briefResultsDescription" : "IABP did not reduce mortality at 30 days", | ||
"published" : " | "published" : "2012-10-10", | ||
"pageName" : " | "pageName" : "IABP-SHOCK II", | ||
"diseases" : " | "diseases" : "Acute Coronary Syndrome;Myocardial Infarction;Shock", | ||
"abbreviation" : " | "abbreviation" : "IABP-SHOCK II", | ||
"title" : " | "title" : "Intraaortic Balloon Support for Myocardial Infarction with Cardiogenic Shock", | ||
"pmid" : " | "pmid" : "22920912" | ||
}, | }, | ||
{ | { | ||
"timestamp" : " | "timestamp" : "2019-05-23T17:29:10Z", | ||
"briefDesignDescription" : " | "briefDesignDescription" : "Adjuvant cisplatin in resected NSCLC", | ||
"fulltexturl" : "http://www.nejm.org/doi/full/10.1056/ | "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa031644", | ||
"pageid" : | "pageid" : 2503, | ||
"pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/ | "pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa031644", | ||
"trainingLevel" : " | "trainingLevel" : "Fellow", | ||
"citation" : " | "citation" : "Arriagada R, <i>et al</i>. \"Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer\". <i>The New England Journal of Medicine</i>. 2004. 350(4):351-360.", | ||
"subspecialties" : " | "subspecialties" : "Oncology", | ||
"expansion" : "", | "expansion" : "International Adjuvant Lung Cancer Trial", | ||
"statusUsableDate" : " | "statusUsableDate" : "2019-05-23", | ||
"briefResultsDescription" : " | "briefResultsDescription" : "Adjuvant cisplatin improves 5-year OS in resected NSCLC", | ||
"published" : " | "published" : "2004-01-22", | ||
"pageName" : " | "pageName" : "IALT", | ||
"diseases" : " | "diseases" : "Lung Cancer", | ||
"abbreviation" : " | "abbreviation" : "IALT", | ||
"title" : " | "title" : "Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer", | ||
"pmid" : " | "pmid" : "14736927" | ||
}, | }, | ||
{ | { | ||
"timestamp" : " | "timestamp" : "2021-11-04T17:33:05Z", | ||
"briefDesignDescription" : " | "briefDesignDescription" : "Second-line ibrutinib in WM", | ||
"fulltexturl" : "http://www.nejm.org/doi/full/10.1056/ | "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1501548", | ||
"pageid" : | "pageid" : 2660, | ||
"pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/ | "pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa1501548", | ||
"trainingLevel" : " | "trainingLevel" : "Fellow", | ||
"citation" : " | "citation" : "Treon SP, <i>et al</i>. \"Ibrutinib in Previously Treated Waldenstrom Macroglobulinemia\". <i>The New England Journal of Medicine</i>. 2015. 372(15):1430-1440.", | ||
"subspecialties" : "Hematology | "subspecialties" : "Hematology", | ||
"expansion" : | "expansion" : null, | ||
"statusUsableDate" : " | "statusUsableDate" : "2015-12-01", | ||
"briefResultsDescription" : " | "briefResultsDescription" : "Ibrutinib is safe and effective in previously treated WM", | ||
"published" : " | "published" : "2015-04-09", | ||
"pageName" : " | "pageName" : "Ibrutinib in Waldenstrom macroglobulinemia", | ||
"diseases" : " | "diseases" : "Lymphoma;Waldenström Macroglobulinemia", | ||
"abbreviation" : | "abbreviation" : null, | ||
"title" : " | "title" : "Ibrutinib in Previously Treated Waldenstrom Macroglobulinemia", | ||
"pmid" : " | "pmid" : "25853747" | ||
}, | }, | ||
{ | { | ||
"timestamp" : "2020- | "timestamp" : "2020-02-10T07:03:58Z", | ||
"briefDesignDescription" : " | "briefDesignDescription" : "Ibrutinib-rituximab vs. FCR in untreated CLL", | ||
"fulltexturl" : "http://www.nejm.org/doi/full/10.1056/ | "fulltexturl" : "https://www.nejm.org/doi/full/10.1056/NEJMoa1817073", | ||
"pageid" : | "pageid" : 4175, | ||
"pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/ | "pdfurl" : "https://www.nejm.org/doi/pdf/10.1056/NEJMoa1817073", | ||
"trainingLevel" : " | "trainingLevel" : "Fellow", | ||
"citation" : " | "citation" : "Shanafelt TD, <i>et al</i>. \"Ibrutinib-Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia\". <i>The New England Journal of Medicine</i>. 2019. 381(5):432-43.", | ||
"subspecialties" : "Cardiology", | "subspecialties" : "Hematology;Oncology", | ||
"expansion" : " | "expansion" : "", | ||
"statusUsableDate" : " | "statusUsableDate" : "2020-02-09", | ||
"briefResultsDescription" : " | "briefResultsDescription" : "IR improved survival over FCR in untreated CLL", | ||
"published" : " | "published" : "2019-08-01", | ||
"pageName" : " | "pageName" : "Ibrutinib-Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia", | ||
"diseases" : " | "diseases" : "Chronic Lymphocytic Leukemia;Small Lymphocytic Lymphoma", | ||
"abbreviation" : " | "abbreviation" : "E1912", | ||
"title" : " | "title" : "Ibrutinib-Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia", | ||
"pmid" : " | "pmid" : "31365801" | ||
}, | |||
{ | |||
"timestamp" : "2018-10-16T05:02:38Z", | |||
"briefDesignDescription" : "Colchicine in the first episode of acute pericarditis", | |||
"fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1208536", | |||
"pageid" : 1729, | |||
"pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa1208536", | |||
"trainingLevel" : "Intern", | |||
"citation" : "Imazio M, <i>et al</i>. \"A Randomized Trial of Colchicine for Acute Pericarditis\". <i>The New England Journal of Medicine</i>. 2013. 369(16):1522-1528.", | |||
"subspecialties" : "Cardiology", | |||
"expansion" : "Evaluation of additive benefit of colchicine to conventional therapy in acute pericarditis", | |||
"statusUsableDate" : "2014-01-01", | |||
"briefResultsDescription" : "Colchicine reduces incessant or recurrent acute pericarditis when used in first episode", | |||
"published" : "2013-10-17", | |||
"pageName" : "ICAP", | |||
"diseases" : "Pericarditis", | |||
"abbreviation" : "ICAP", | |||
"title" : "A Randomized Trial of Colchicine for Acute Pericarditis", | |||
"pmid" : "23992557" | |||
}, | }, | ||
{ | { | ||
"timestamp" : "2017-12-03T22: | "timestamp" : "2017-12-03T22:36:07Z", | ||
"briefDesignDescription" : " | "briefDesignDescription" : "Early vs. late dialysis in CKD", | ||
"fulltexturl" : "http://www.nejm.org/doi/full/10.1056/ | "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1000552", | ||
"pageid" : | "pageid" : 1020, | ||
"pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/ | "pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa1000552", | ||
"trainingLevel" : "Resident", | "trainingLevel" : "Resident", | ||
"citation" : " | "citation" : "Cooper BA, <i>et al</i>. \"A Randomized, Controlled Trial of Early versus Late Initiation of Dialysis\". <i>The New England Journal of Medicine</i>. 2010. 363(7):609-619.", | ||
"subspecialties" : " | "subspecialties" : "Nephrology", | ||
"expansion" : " | "expansion" : "Initiating Dialysis Early and Late", | ||
"statusUsableDate" : " | "statusUsableDate" : "2012-10-01", | ||
"briefResultsDescription" : " | "briefResultsDescription" : "No difference in survival or clinical outcomes", | ||
"published" : " | "published" : "2010-08-12", | ||
"pageName" : " | "pageName" : "IDEAL", | ||
"diseases" : " | "diseases" : "Chronic Kidney Disease", | ||
"abbreviation" : " | "abbreviation" : "IDEAL", | ||
"title" : " | "title" : "A Randomized, Controlled Trial of Early versus Late Initiation of Dialysis", | ||
"pmid" : " | "pmid" : "20581422" | ||
}, | }, | ||
{ | { | ||
"timestamp" : " | "timestamp" : "2019-03-27T18:27:05Z", | ||
"briefDesignDescription" : "Early | "briefDesignDescription" : "Early vs. delayed RRT in septic shock", | ||
"fulltexturl" : " | "fulltexturl" : "https://www.nejm.org/doi/full/10.1056/NEJMoa1803213", | ||
"pageid" : | "pageid" : 3746, | ||
"pdfurl" : " | "pdfurl" : "https://www.nejm.org/doi/pdf/10.1056/NEJMoa1803213", | ||
"trainingLevel" : "Resident", | "trainingLevel" : "Resident", | ||
"citation" : " | "citation" : "Barbar SD, <i>et al</i>. \"Timing of renal-replacement therapy in patients with acute kidney injury and sepsis\". <i>The New England Journal of Medicine</i>. 2018. 379(15):1431-1442.", | ||
"subspecialties" : " | "subspecialties" : "Critical Care;Nephrology", | ||
"expansion" : " | "expansion" : "Initiation of Dialysis Early Versus Delayed in the Intensive Care Unit", | ||
"statusUsableDate" : " | "statusUsableDate" : "2019-03-27", | ||
"briefResultsDescription" : " | "briefResultsDescription" : "No benefit from early initiated RRT in septic shock", | ||
"published" : " | "published" : "2018-10-11", | ||
"pageName" : " | "pageName" : "IDEAL-ICU", | ||
"diseases" : " | "diseases" : "Acute Kidney Injury;Septic Shock", | ||
"abbreviation" : " | "abbreviation" : "IDEAL-ICU", | ||
"title" : " | "title" : "Timing of renal-replacement therapy in patients with acute kidney injury and sepsis", | ||
"pmid" : " | "pmid" : "30304656" | ||
}, | }, | ||
{ | { | ||
"timestamp" : "2017-12-03T22: | "timestamp" : "2017-12-03T22:36:08Z", | ||
"briefDesignDescription" : " | "briefDesignDescription" : "ARBs in diabetic nephropathy", | ||
"fulltexturl" : "http://www.nejm.org/doi/full/10.1056/ | "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa011303", | ||
"pageid" : | "pageid" : 2670, | ||
"pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/ | "pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa011303", | ||
"trainingLevel" : " | "trainingLevel" : "Resident", | ||
"citation" : " | "citation" : "Lewis EJ, <i>et al</i>. \"Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes\". <i>The New England Journal of Medicine</i>. 2001. 345(12):851-860.", | ||
"subspecialties" : " | "subspecialties" : "Nephrology;Endocrinology", | ||
"expansion" : | "expansion" : "Irbesartan Diabetic Nephropathy Trial", | ||
"statusUsableDate" : " | "statusUsableDate" : "2016-01-01", | ||
"briefResultsDescription" : " | "briefResultsDescription" : "ARBs prevent progression of T2DM nephropathy", | ||
"published" : " | "published" : "2001-09-20", | ||
"pageName" : " | "pageName" : "IDNT", | ||
"diseases" : " | "diseases" : "Diabetic Nephropathy;Diabetes Mellitus", | ||
"abbreviation" : | "abbreviation" : "IDNT", | ||
"title" : " | "title" : "Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes", | ||
"pmid" : " | "pmid" : "11565517" | ||
}, | }, | ||
{ | { | ||
"timestamp" : " | "timestamp" : "2017-12-03T22:36:10Z", | ||
"briefDesignDescription" : " | "briefDesignDescription" : "iFR vs. FFR for PCI", | ||
"fulltexturl" : "http://www. | "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1616540", | ||
"pageid" : | "pageid" : 2926, | ||
"pdfurl" : "", | "pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa1616540", | ||
"trainingLevel" : "Resident", | "trainingLevel" : "Resident", | ||
"citation" : " | "citation" : "Gotberg M, <i>et al</i>. \"Spontaneous wave-free ratio versus fractional flow reserve to guide PCI\". <i>The New England Journal of Medicine</i>. 2017. 376(19):1813-1823.", | ||
"subspecialties" : "Cardiology", | "subspecialties" : "Cardiology", | ||
"expansion" : " | "expansion" : "Instantaneous Wave-free Ratio versus Fractional Flow Reserve in Patients with Stable Angina Pectoris or Acute Coronary Syndrome", | ||
"statusUsableDate" : " | "statusUsableDate" : "2017-05-01", | ||
"briefResultsDescription" : " | "briefResultsDescription" : "iFR noninferior to FFR for PCI", | ||
"published" : " | "published" : "2017-05-11", | ||
"pageName" : " | "pageName" : "IFR-SWEDEHEART", | ||
"diseases" : " | "diseases" : "Coronary Artery Disease", | ||
"abbreviation" : " | "abbreviation" : "iFR-SWEDEHEART", | ||
"title" : " | "title" : "Spontaneous wave-free ratio versus fractional flow reserve to guide PCI", | ||
"pmid" : " | "pmid" : "28317438" | ||
}, | }, | ||
{ | { | ||
"timestamp" : " | "timestamp" : "2017-12-14T19:46:19Z", | ||
"briefDesignDescription" : " | "briefDesignDescription" : "Ezetimibe+simvastatin after ACS", | ||
"fulltexturl" : "http://www. | "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1410489", | ||
"pageid" : | "pageid" : 2369, | ||
"pdfurl" : "http://www. | "pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa1410489", | ||
"trainingLevel" : " | "trainingLevel" : "Intern", | ||
"citation" : " | "citation" : "Cannon CP, <i>et al</i>. \"Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes\". <i>The New England Journal of Medicine</i>. 2015. 375(25):2387-2397.", | ||
"subspecialties" : "Cardiology", | "subspecialties" : "Cardiology", | ||
"expansion" : " | "expansion" : "IMProved Reduction of Outcomes: Vytorin Efficacy International Trial", | ||
"statusUsableDate" : " | "statusUsableDate" : "2015-06-01", | ||
"briefResultsDescription" : " | "briefResultsDescription" : "Ezetimibe improves CV outcomes when added to statin", | ||
"published" : " | "published" : "2015-06-18", | ||
"pageName" : " | "pageName" : "IMPROVE-IT", | ||
"diseases" : " | "diseases" : "Hyperlipidemia;Acute Coronary Syndrome;Myocardial Infarction", | ||
"abbreviation" : " | "abbreviation" : "IMPROVE-IT", | ||
"title" : " | "title" : "Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes", | ||
"pmid" : " | "pmid" : "26039521" | ||
}, | }, | ||
{ | { | ||
"timestamp" : " | "timestamp" : "2018-03-30T14:11:39Z", | ||
"briefDesignDescription" : " | "briefDesignDescription" : "Nintedanib in IPF", | ||
"fulltexturl" : "http://www.nejm.org/doi/full/10.1056/ | "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1402584", | ||
"pageid" : | "pageid" : 2934, | ||
"pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/ | "pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa1402584", | ||
"trainingLevel" : " | "trainingLevel" : "Resident", | ||
"citation" : " | "citation" : "Richeldi L, <i>et al</i>. \"Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis\". <i>The New England Journal of Medicine</i>. 2014. 370(22):2071-2082.", | ||
"subspecialties" : " | "subspecialties" : "Pulmonology", | ||
"expansion" : " | "expansion" : "", | ||
"statusUsableDate" : " | "statusUsableDate" : "2018-03-30", | ||
"briefResultsDescription" : " | "briefResultsDescription" : "Nintedanib slows progression of IPF", | ||
"published" : " | "published" : "2014-05-29", | ||
"pageName" : " | "pageName" : "INPULSIS Trials", | ||
"diseases" : " | "diseases" : "Idiopathic Pulmonary Fibrosis", | ||
"abbreviation" : " | "abbreviation" : "INPULSIS I and II", | ||
"title" : " | "title" : "Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis", | ||
"pmid" : " | "pmid" : "24836310" | ||
}, | }, | ||
{ | { | ||
"timestamp" : " | "timestamp" : "2017-12-03T22:36:12Z", | ||
"briefDesignDescription" : " | "briefDesignDescription" : "Early vs. delayed ART in HIV", | ||
"fulltexturl" : "http://www.nejm.org/doi/full/10.1056/ | "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1506816", | ||
"pageid" : | "pageid" : 2468, | ||
"pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/ | "pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa1506816", | ||
"trainingLevel" : " | "trainingLevel" : "Student", | ||
"citation" : " | "citation" : "INSIGHT START Writers. \"Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection\". <i>The New England Journal of Medicine</i>. 2015. 373(9):795-807.", | ||
"subspecialties" : " | "subspecialties" : "Infectious Disease", | ||
"expansion" : | "expansion" : null, | ||
"statusUsableDate" : " | "statusUsableDate" : "2016-01-01", | ||
"briefResultsDescription" : " | "briefResultsDescription" : "Less complications with early ART", | ||
"published" : " | "published" : "2015-08-27", | ||
"pageName" : " | "pageName" : "INSIGHT START", | ||
"diseases" : " | "diseases" : "HIV", | ||
"abbreviation" : " | "abbreviation" : "START", | ||
"title" : " | "title" : "Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection", | ||
"pmid" : " | "pmid" : "26192873" | ||
}, | }, | ||
{ | { | ||
"timestamp" : "2017-12-03T22: | "timestamp" : "2017-12-03T22:36:14Z", | ||
"briefDesignDescription" : " | "briefDesignDescription" : "ART in primary HIV prevention", | ||
"fulltexturl" : "http://www.nejm.org/doi/full/10.1056/ | "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1011205", | ||
"pageid" : | "pageid" : 1100, | ||
"pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/ | "pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa1011205", | ||
"trainingLevel" : " | "trainingLevel" : "intern", | ||
"citation" : " | "citation" : "Grant RM, <i>et al</i>. \"Preexposure chemoprophylaxis for HIV prevention in men who have sex with men\". <i>The New England Journal of Medicine</i>. 2010. 363(27):2587-2599.", | ||
"subspecialties" : " | "subspecialties" : "Infectious Disease;Preventive Medicine", | ||
"expansion" : " | "expansion" : "Iniciativa Profilaxis Pre Exposicion (\"Preexposure Prophylaxis Initiative\")", | ||
"statusUsableDate" : " | "statusUsableDate" : "2013-02-01", | ||
"briefResultsDescription" : " | "briefResultsDescription" : "ART reduces tranmission of HIV among MSM", | ||
"published" : " | "published" : "2010-12-30", | ||
"pageName" : " | "pageName" : "IPrEx", | ||
"diseases" : " | "diseases" : "HIV", | ||
"abbreviation" : " | "abbreviation" : "iPrEx", | ||
"title" : " | "title" : "Preexposure chemoprophylaxis for HIV prevention in men who have sex with men", | ||
"pmid" : " | "pmid" : "21091279" | ||
}, | }, | ||
{ | { | ||
"timestamp" : " | "timestamp" : "2017-12-03T22:36:15Z", | ||
"briefDesignDescription" : " | "briefDesignDescription" : "Imatinib vs. IFNα/cytarabine in CML", | ||
"fulltexturl" : "http://www.nejm.org/doi/full/10.1056/ | "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa022457", | ||
"pageid" : | "pageid" : 1076, | ||
"pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/ | "pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa022457", | ||
"trainingLevel" : " | "trainingLevel" : "Student", | ||
"citation" : " | "citation" : "O'Brien SG, <i>et al</i>. \"Imatinib Compared with Interferon and Low-Dose Cytarabine for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia\". <i>The New England Journal of Medicine</i>. 2003. 384(11):994-1004.", | ||
"subspecialties" : " | "subspecialties" : "Hematology;Oncology", | ||
"expansion" : " | "expansion" : "International Randomized Study of Interferon and STI571", | ||
"statusUsableDate" : " | "statusUsableDate" : "2012-11-01", | ||
"briefResultsDescription" : " | "briefResultsDescription" : "Imatinib delays disease progression", | ||
"published" : " | "published" : "2003-03-13", | ||
"pageName" : " | "pageName" : "IRIS", | ||
"diseases" : " | "diseases" : "Chronic Myeloid Leukemia;Myeloproliferative Neoplasms", | ||
"abbreviation" : " | "abbreviation" : "IRIS", | ||
"title" : " | "title" : "Imatinib Compared with Interferon and Low-Dose Cytarabine for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia", | ||
"pmid" : " | "pmid" : "12637609" | ||
}, | }, | ||
{ | { | ||
"timestamp" : " | "timestamp" : "2024-05-20T13:33:05Z", | ||
"briefDesignDescription" : " | "briefDesignDescription" : "IV iron in critical illness", | ||
"fulltexturl" : " | "fulltexturl" : "https://link.springer.com/article/10.1007%2Fs00134-016-4465-6", | ||
"pageid" : | "pageid" : 3651, | ||
"pdfurl" : "", | "pdfurl" : "https://link.springer.com/content/pdf/10.1007/s00134-016-4465-6.pdf", | ||
"trainingLevel" : " | "trainingLevel" : "Fellow", | ||
"citation" : " | "citation" : "Litton E, <i>et al</i>. \"Intravenous iron or placebo for anaemia in intensive care: the IRONMAN multicentre randomized blinded trial\". <i>Intensive Care Med</i>. 2016. 42:1715-1722.", | ||
"subspecialties" : " | "subspecialties" : "Critical Care;Hematology", | ||
"expansion" : "", | "expansion" : "", | ||
"statusUsableDate" : " | "statusUsableDate" : "2024-04-30", | ||
"briefResultsDescription" : " | "briefResultsDescription" : "IV iron did not reduce transfusion requirements", | ||
"published" : " | "published" : "2016-11-01", | ||
"pageName" : " | "pageName" : "IRONMAN", | ||
"diseases" : " | "diseases" : "Anemia;Critical Illness", | ||
"abbreviation" : " | "abbreviation" : "IRONMAN", | ||
"title" : " | "title" : "Intravenous iron or placebo for anaemia in intensive care: the IRONMAN multicentre randomized blinded trial", | ||
"pmid" : " | "pmid" : "27686346" | ||
}, | }, | ||
{ | { | ||
"timestamp" : " | "timestamp" : "2017-12-03T22:36:17Z", | ||
"briefDesignDescription" : " | "briefDesignDescription" : "Oral iron vs. placebo in HFrEF and iron deficiency", | ||
"fulltexturl" : "http:// | "fulltexturl" : "http://jamanetwork.com/journals/jama/article-abstract/2626574", | ||
"pageid" : | "pageid" : 2941, | ||
"pdfurl" : "http:// | "pdfurl" : "http://jamanetwork.com/journals/jama/article-abstract/2626574", | ||
"trainingLevel" : " | "trainingLevel" : "Resident", | ||
"citation" : " | "citation" : "Lewis GD, <i>et al</i>. \"Effect of oral iron repletion on exercise capacity in patients with heart failure with reduced ejection fraction and iron deficiency\". <i>JAMA</i>. 2017. 317(19):1958-66.", | ||
"subspecialties" : " | "subspecialties" : "Cardiology", | ||
"expansion" : " | "expansion" : "Iron Repletion Effects on Oxygen Uptake in Heart Failure", | ||
"statusUsableDate" : " | "statusUsableDate" : "2017-07-01", | ||
"briefResultsDescription" : " | "briefResultsDescription" : "Oral iron not superior to placebo in HFrEF", | ||
"published" : " | "published" : "2017-07-09", | ||
"pageName" : " | "pageName" : "IRONOUT-HF", | ||
"diseases" : " | "diseases" : "Heart Failure", | ||
"abbreviation" : " | "abbreviation" : "IRONOUT-HF", | ||
"title" : "Effect of | "title" : "Effect of oral iron repletion on exercise capacity in patients with heart failure with reduced ejection fraction and iron deficiency", | ||
"pmid" : " | "pmid" : "28510680" | ||
}, | }, | ||
{ | { | ||
"timestamp" : " | "timestamp" : "2019-10-17T17:39:50Z", | ||
"briefDesignDescription" : " | "briefDesignDescription" : "Ticagrelor vs. prasugrel in ACS", | ||
"fulltexturl" : " | "fulltexturl" : "https://www.nejm.org/doi/full/10.1056/NEJMoa1908973", | ||
"pageid" : | "pageid" : 4100, | ||
"pdfurl" : " | "pdfurl" : "https://www.nejm.org/doi/pdf/10.1056/NEJMoa1908973", | ||
"trainingLevel" : "Resident", | "trainingLevel" : "Resident", | ||
"citation" : " | "citation" : "Schupke S <i>et al</i>. \"Ticagrelor or prasugrel in patients with acute coronary syndromes\". <i>New Engl J Med</i>. 2019. 1-11.", | ||
"subspecialties" : " | "subspecialties" : "Cardiology", | ||
"expansion" : " | "expansion" : "Intracoronary Stenting and Antithrombotic Regimen: Rapid Early Action for Coronary Treatment 5 Trial", | ||
"statusUsableDate" : " | "statusUsableDate" : "2019-10-17", | ||
"briefResultsDescription" : " | "briefResultsDescription" : "Prasugrel superior to ticagrelor in acute coronary syndromes", | ||
"published" : " | "published" : "2019-09-01", | ||
"pageName" : " | "pageName" : "ISAR-REACT 5", | ||
"diseases" : " | "diseases" : "Coronary Artery Disease", | ||
"abbreviation" : " | "abbreviation" : "ISAR-REACT 5", | ||
"title" : " | "title" : "Ticagrelor or prasugrel in patients with acute coronary syndromes", | ||
"pmid" : " | "pmid" : "31475799" | ||
}, | }, | ||
{ | { | ||
"timestamp" : " | "timestamp" : "2021-01-30T20:57:06Z", | ||
"briefDesignDescription" : " | "briefDesignDescription" : "Triple therapy for 6w vs. 6m after DES", | ||
"fulltexturl" : " | "fulltexturl" : "http://content.onlinejacc.org/article.aspx?articleID", | ||
"pageid" : | "pageid" : 2812, | ||
"pdfurl" : " | "pdfurl" : "https://www.jacc.org/doi/pdf/10.1016/j.jacc.2015.02.050", | ||
"trainingLevel" : "Intern", | |||
"citation" : "Fiedler KA <i>et al</i>. \"Duration of triple therapy in patients requiring oral anticoagulation after drug-eluting stent implantation\". <i>J Am Coll Cardiol</i>. 2015. 65(16):1619-30.", | |||
"subspecialties" : "Cardiology", | |||
"expansion" : "Triple therapy in Patients who Require Oral Anticoagulation After Drug-Eluting Stent Implantation", | |||
"statusUsableDate" : "2016-10-01", | |||
"briefResultsDescription" : "Triple therapy for 6 weeks not superior to 6 months in regards to net clinical outcome", | |||
"published" : "2015-04-28", | |||
"pageName" : "ISAR-TRIPLE", | |||
"diseases" : "Coronary Artery Disease;Atrial Fibrillation", | |||
"abbreviation" : "ISAR-TRIPLE", | |||
"title" : "Duration of triple therapy in patients requiring oral anticoagulation after drug-eluting stent implantation", | |||
"pmid" : "25908066" | |||
}, | |||
{ | |||
"timestamp" : "2021-04-07T17:13:36Z", | |||
"briefDesignDescription" : "PCI/CABG vs. medical therapy in stable CAD", | |||
"fulltexturl" : "https://www.nejm.org/doi/10.1056/NEJMoa1915922", | |||
"pageid" : 4153, | |||
"pdfurl" : "https://www.nejm.org/doi/pdf/10.1056/NEJMoa1915922", | |||
"trainingLevel" : "Resident", | "trainingLevel" : "Resident", | ||
"citation" : "Maron DJ, <i>et al</i>. \"Initial Invasive or Conservative Strategy for Stable Coronary Disease\". <i>The New England Journal of Medicine</i>. 2020. 382(15):1395-1407.", | |||
"subspecialties" : "Cardiology", | |||
"expansion" : "International Study of Comparative Health Effectiveness with Medical and Invasive Approaches", | |||
"statusUsableDate" : "2021-01-28", | |||
"briefResultsDescription" : "No difference between PCI/CABG and medical therapy in stable CAD with moderate-severe ischemia", | |||
"published" : "2020-04-09", | |||
"pageName" : "ISCHEMIA", | |||
"citation" : "Maron DJ, <i>et al</i>. \"Initial Invasive or Conservative Strategy for Stable Coronary Disease\". <i>The New England Journal of Medicine</i>. 2020. 382(15):1395-1407.", | |||
"subspecialties" : "Cardiology", | |||
"expansion" : "International Study of Comparative Health Effectiveness with Medical and Invasive Approaches", | |||
"statusUsableDate" : "2021-01-28", | |||
"briefResultsDescription" : "No difference between PCI/CABG and medical therapy in stable CAD with moderate-severe ischemia", | |||
"published" : "2020-04-09", | |||
"pageName" : "ISCHEMIA | |||
"diseases" : "Coronary Artery Disease", | "diseases" : "Coronary Artery Disease", | ||
"abbreviation" : " | "abbreviation" : "ISCHEMIA", | ||
"title" : " | "title" : "Initial Invasive or Conservative Strategy for Stable Coronary Disease", | ||
"pmid" : "32227755" | |||
"pmid" : " | |||
}, | }, | ||
{ | { | ||